Date,Open,High,Low,Close,Volume,Dividends,Stock Splits,SMA_10,SMA_40,SMA_120,Close_10_%_D,10_40_%_D,40_120_%_D,RSI,earningsGrowth,revenueGrowth,profitMargins,grossMargins,returnOnEquity,debtToEquity,priceToBook,forwardPE,longName,sector,longBusinessSummary
2022-06-27,64.0,66.69999694824219,60.400001525878906,60.79999923706055,36657,0.0,0.0,,,,,,,,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-06-28,60.79999923706055,63.5,60.0,62.20000076293945,33084,0.0,0.0,,,,,,,100.0,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-06-29,62.20000076293945,62.29999923706055,60.0,60.79999923706055,11316,0.0,0.0,,,,,,,48.148148148148145,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-06-30,60.79999923706055,64.0999984741211,59.20000076293945,61.099998474121094,14404,0.0,0.0,,,,,,,53.68954944934793,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-07-01,60.0,61.20000076293945,57.20000076293945,58.099998474121094,36424,0.0,0.0,,,,,,,24.96132597320178,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-07-04,57.900001525878906,62.5,57.79999923706055,60.900001525878906,38942,0.0,0.0,,,,,,,51.20467118384852,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-07-05,61.0,63.400001525878906,57.400001525878906,57.5,29987,0.0,0.0,,,,,,,35.135703273955855,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-07-06,58.900001525878906,58.900001525878906,55.599998474121094,56.20000076293945,49228,0.0,0.0,,,,,,,31.115042202350907,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-07-07,56.400001525878906,67.9000015258789,56.400001525878906,66.9000015258789,78871,0.0,0.0,,,,,,,65.80234516233001,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-07-08,68.9000015258789,73.4000015258789,67.19999694824219,67.5,47130,0.0,0.0,61.2,,,10.294117647058819,,,66.81156083362058,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-07-11,67.5,68.5,64.0999984741211,67.0,14088,0.0,0.0,61.820000076293944,,,8.37916518491307,,,65.08774282353347,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-07-12,67.0,67.0,64.30000305175781,66.30000305175781,9311,0.0,0.0,62.23000030517578,,,6.540258278358911,,,62.65062768051245,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-07-13,64.4000015258789,66.19999694824219,63.099998474121094,66.19999694824219,8639,0.0,0.0,62.77000007629395,,,5.464388828706776,,,62.291769748534385,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-07-14,66.19999694824219,67.9000015258789,60.599998474121094,61.0,19638,0.0,0.0,62.760000228881836,,,-2.8043343251485404,,,47.16415522720084,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-07-15,61.29999923706055,62.400001525878906,59.70000076293945,62.400001525878906,11662,0.0,0.0,63.19000053405762,,,-1.2501962359581307,,,50.63973578471477,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-07-18,62.400001525878906,65.4000015258789,62.0,63.400001525878906,6736,0.0,0.0,63.44000053405762,,,-0.06305013846467035,,,53.01709466700313,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-07-19,63.400001525878906,64.9000015258789,62.0,64.9000015258789,6890,0.0,0.0,64.18000068664551,,,1.1218461070898829,,,56.40861106174858,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-07-20,65.0,68.5,63.5,67.80000305175781,18713,0.0,0.0,65.34000091552734,,,3.7649251633938667,,,62.10417884103899,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-07-21,68.0,70.5,67.5,69.0,20245,0.0,0.0,65.55000076293945,,,5.2631566695741485,,,64.18922936464654,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-07-22,74.0,89.4000015258789,70.9000015258789,73.0,52728,0.0,0.0,66.10000076293946,,,10.43872792347862,,,70.09564759526442,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-07-25,76.30000305175781,76.30000305175781,72.19999694824219,72.69999694824219,19515,0.0,0.0,66.67000045776368,,,9.044542446491494,,,69.17412797446005,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-07-26,72.69999694824219,76.0,71.4000015258789,74.0,15628,0.0,0.0,67.44000015258788,,,9.727164639041579,,,70.95598776550148,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-07-27,74.19999694824219,76.30000305175781,73.19999694824219,74.5999984741211,8851,0.0,0.0,68.28000030517578,,,9.25600196352994,,,71.76714203318726,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-07-28,75.0999984741211,81.5999984741211,75.0999984741211,80.4000015258789,25239,0.0,0.0,70.22000045776367,,,14.497295644762003,,,78.12666579764888,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-07-29,80.4000015258789,83.9000015258789,79.4000015258789,83.0,32278,0.0,0.0,72.28000030517578,,,14.83121146868146,,,80.27194390043105,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-08-01,84.0999984741211,85.0999984741211,81.0,83.0,18453,0.0,0.0,74.2400001525879,,,11.799568735731937,,,80.27194390043105,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-08-02,83.0,84.9000015258789,82.5,84.0,7877,0.0,0.0,76.15,,,10.308601444517391,,,81.09884437809133,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-08-03,85.0,97.80000305175781,85.0,89.30000305175781,48571,0.0,0.0,78.3,,,14.048535187430161,,,84.74775702545114,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-08-04,89.30000305175781,92.9000015258789,86.9000015258789,87.9000015258789,33888,0.0,0.0,80.19000015258788,,,9.614666864472134,,,80.33589600190628,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-08-05,87.80000305175781,91.80000305175781,86.0999984741211,88.80000305175781,45539,0.0,0.0,81.77000045776367,,,8.597288192049502,,,81.01994999598367,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-08-08,89.9000015258789,89.9000015258789,84.0999984741211,89.19999694824219,24669,0.0,0.0,83.42000045776368,,,6.9287898091117555,,,81.33079004059968,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-08-09,89.19999694824219,90.5,84.19999694824219,85.0999984741211,32832,0.0,0.0,84.53000030517578,,,0.6743146420057651,,,68.87876522876415,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-08-10,86.69999694824219,87.5999984741211,81.9000015258789,84.69999694824219,14841,0.0,0.0,85.5400001525879,,,-0.9820004709460978,,,67.78832336809137,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-08-11,85.0,89.9000015258789,85.0,87.9000015258789,12051,0.0,0.0,86.2900001525879,,,1.8658029556658053,,,71.65444694764403,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-08-12,88.0,89.80000305175781,85.30000305175781,87.0999984741211,20459,0.0,0.0,86.7,,,0.4613592550416273,,,69.41149721219989,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-08-15,86.9000015258789,88.9000015258789,85.5,86.9000015258789,17311,0.0,0.0,87.09000015258789,,,-0.2181635392996822,,,68.83142831054221,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-08-16,86.9000015258789,88.0,84.5,84.9000015258789,19314,0.0,0.0,87.18000030517578,,,-2.61527732428961,,,63.148135727656324,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-08-17,84.9000015258789,87.9000015258789,84.9000015258789,86.30000305175781,17028,0.0,0.0,86.88000030517578,,,-0.6675843132834552,,,65.30752862405308,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-08-18,86.0999984741211,87.30000305175781,83.4000015258789,84.5,17914,0.0,0.0,86.5400001525879,,,-2.3572915980944673,,,60.406520299136204,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-08-19,84.5,85.0,78.0999984741211,81.80000305175781,28938,0.0,0.0,85.84000015258789,73.72750034332276,,-4.706427182722088,16.428740636616627,,53.87540361655607,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-08-22,81.80000305175781,82.19999694824219,78.4000015258789,78.5999984741211,15412,0.0,0.0,84.78000030517578,74.17250032424927,,-7.289457193688399,14.301122295399535,,47.34222808500859,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-08-23,78.5,81.0999984741211,77.0999984741211,78.19999694824219,15230,0.0,0.0,84.09000015258789,74.57250022888184,,-7.004403845472506,12.762747520191015,,46.58182129393797,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-08-24,78.0999984741211,81.30000305175781,76.0,81.30000305175781,7106,0.0,0.0,83.75000076293945,75.08500032424926,,-2.925370374761592,11.540254912793491,,52.89630508907397,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-08-25,81.30000305175781,84.80000305175781,80.0,84.80000305175781,10982,0.0,0.0,83.44000091552735,75.67750043869019,,1.62991625276622,10.257342581136013,,58.81562050414492,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-08-26,85.5,86.19999694824219,80.9000015258789,81.0,20200,0.0,0.0,82.83000106811524,76.25000047683716,,-2.209345701457056,8.629508918202458,,51.28081554929928,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-08-29,84.80000305175781,84.80000305175781,77.5,80.0,11534,0.0,0.0,82.14000091552734,76.72750043869019,,-2.6053090962685914,7.054185847174914,,49.48423405511363,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-08-30,80.5,82.69999694824219,78.5999984741211,78.80000305175781,8144,0.0,0.0,81.53000106811524,77.26000051498413,,-3.3484582124273703,5.526793327296148,,47.340883621069096,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-08-31,78.80000305175781,81.19999694824219,75.9000015258789,79.5999984741211,2811,0.0,0.0,80.86000061035156,77.84500045776367,,-1.5582514552555735,3.8730812959834653,,48.92903692435197,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-09-01,80.5,80.5,74.0999984741211,75.0,27176,0.0,0.0,79.91000061035156,78.0475004196167,,-6.144413180889798,2.3863675078910496,,41.22924325573745,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-09-02,76.19999694824219,78.30000305175781,75.0999984741211,77.9000015258789,8534,0.0,0.0,79.52000045776367,78.30750045776367,,-2.0372219851095363,1.5483829683134707,,46.90225543626983,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-09-05,74.0,76.5,72.19999694824219,74.80000305175781,23510,0.0,0.0,79.14000091552734,78.50250053405762,,-5.4839497265130985,0.81207652894209,,42.21161309933136,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-09-06,76.0,76.69999694824219,74.19999694824219,76.19999694824219,14554,0.0,0.0,78.94000091552735,78.75000038146973,,-3.4709956112328957,0.24127051826951518,,44.89203001675435,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-09-07,80.0,80.0,74.19999694824219,77.19999694824219,12886,0.0,0.0,78.53000030517578,79.02500038146972,,-1.6936245406405912,-0.6263841491989652,,46.79052432321277,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-09-08,80.0,81.19999694824219,78.19999694824219,80.5,20425,0.0,0.0,78.1,79.51250038146972,,3.072983354673503,-1.7764507149103663,,52.59446497818928,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-09-09,81.69999694824219,83.5999984741211,79.80000305175781,83.19999694824219,22278,0.0,0.0,78.31999969482422,80.03250026702881,,6.2308443212883,-2.1397564320630043,,56.751106744813676,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-09-12,83.19999694824219,84.30000305175781,78.4000015258789,78.9000015258789,27633,0.0,0.0,78.2099998474121,80.42000026702881,,0.8822422705702526,-2.748073131408304,,49.332296231042605,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-09-13,80.80000305175781,80.80000305175781,79.0,79.69999694824219,18863,0.0,0.0,78.29999923706055,80.7900001525879,,1.7879919857253346,-3.0820657393544835,,50.62549966460351,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-09-14,80.0,81.0,78.5,81.0,16749,0.0,0.0,78.43999938964843,81.12000007629395,,3.26364180299752,-3.303748377866067,,52.73656866199982,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-09-15,82.0,87.5999984741211,81.0,87.5999984741211,28622,0.0,0.0,79.69999923706055,81.58500003814697,,9.912169777521198,-2.3104747198689024,,61.69177990567552,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-09-16,87.5,100.5999984741211,85.30000305175781,88.0,219138,0.0,0.0,80.70999908447266,81.96000003814697,,9.032339237047305,-1.525135374685851,,62.159738270101975,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-09-19,88.0,92.0,81.30000305175781,81.4000015258789,55108,0.0,0.0,81.36999893188477,82.1775001525879,,0.036871813184188376,-0.9826305487557487,,51.0736358485008,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-09-20,81.5,83.69999694824219,80.5,80.5,41289,0.0,0.0,81.79999923706055,82.34000015258789,,-1.5892411359235876,-0.6558184533964588,,49.77010193745924,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-09-21,80.5,82.69999694824219,80.0999984741211,80.4000015258789,21398,0.0,0.0,82.11999969482422,82.48500022888183,,-2.094493637770576,-0.44250534405625264,,49.61856984815491,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-09-22,80.0,82.5,76.5,77.5,82320,0.0,0.0,81.81999969482422,82.41250019073486,,-5.279882315982817,-0.7189449349787509,,45.31012192004702,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-09-23,79.4000015258789,82.0,77.5999984741211,80.0,63358,0.0,0.0,81.5,82.33750019073486,,-1.8404907975460123,-1.0171552315710193,,49.3899323979766,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-09-26,80.0999984741211,82.30000305175781,76.19999694824219,76.80000305175781,41790,0.0,0.0,81.2900001525879,82.18250026702881,,-5.52343103998277,-1.0859977629556097,,44.784648167034575,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-09-27,76.80000305175781,89.0,76.80000305175781,77.9000015258789,15649,0.0,0.0,81.11000061035156,82.03000030517578,,-3.9575873015873015,-1.1215405234689053,,46.626976434620516,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-09-28,77.9000015258789,81.0,76.4000015258789,78.4000015258789,24835,0.0,0.0,80.85000076293946,81.7575002670288,,-3.030302058059595,-1.1099892989944078,,47.48471610079024,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-09-29,78.4000015258789,80.69999694824219,78.30000305175781,79.9000015258789,13438,0.0,0.0,80.08000106811524,81.55750026702881,,-0.22477465014420417,-1.8116043209711816,,50.07676021016847,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-09-30,79.69999694824219,79.69999694824219,77.69999694824219,78.5999984741211,19773,0.0,0.0,79.14000091552734,81.3025001525879,,-0.6823381793773714,-2.6598188653509998,,47.871443396761435,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-10-03,79.5,79.9000015258789,74.0999984741211,76.9000015258789,31803,0.0,0.0,78.69000091552735,80.99500026702881,,-2.274748213016268,-2.8458538723405336,,45.075891597013396,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-10-04,76.9000015258789,79.9000015258789,75.5,76.9000015258789,25615,0.0,0.0,78.33000106811524,80.79000034332276,,-1.8256089911103321,-3.044930393308062,,45.075891597013396,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-10-05,77.0,77.0,74.0999984741211,75.0,28480,0.0,0.0,77.79000091552734,80.5475004196167,,-3.586580386542254,-3.423445159345734,,41.9039773161346,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-10-06,75.19999694824219,76.0,75.0,75.19999694824219,5028,0.0,0.0,77.56000061035157,80.23000030517578,,-3.04281026758321,-3.3279318019047377,,42.36373295424529,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-10-07,75.5,77.5999984741211,75.19999694824219,76.30000305175781,10536,0.0,0.0,77.19000091552735,79.9600004196167,,-1.152996311975049,-3.464231477679917,,44.94443744040621,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-10-10,77.0,82.0999984741211,75.0,75.4000015258789,11230,0.0,0.0,77.05000076293945,79.6725004196167,,-2.1414655687507533,-3.291599539195014,,43.238565055384775,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-10-11,75.5,75.9000015258789,73.0999984741211,74.4000015258789,12991,0.0,0.0,76.70000076293945,79.4100004196167,,-2.998695194501067,-3.4126679792936856,,41.360139357497346,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-10-12,76.0999984741211,77.5,74.30000305175781,75.0999984741211,7320,0.0,0.0,76.37000045776367,79.13000030517578,,-1.6629592458166154,-3.4879310460859307,,43.21966233501368,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-10-13,75.0999984741211,76.69999694824219,73.5999984741211,75.69999694824219,8823,0.0,0.0,75.95,78.91000022888184,,-0.3291679417482756,-3.7511091373669134,,44.83444939114537,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-10-14,75.80000305175781,78.30000305175781,75.0999984741211,78.0999984741211,5882,0.0,0.0,75.9,78.81750011444092,,2.898548714257033,-3.701589253915412,,50.85507992760156,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-10-17,77.9000015258789,78.5999984741211,75.69999694824219,77.5,13272,0.0,0.0,75.9599998474121,78.7900001525879,,2.0273830380218993,-3.5918267542773124,,49.40345423391733,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-10-18,76.19999694824219,81.0,76.19999694824219,80.0,11588,0.0,0.0,76.26999969482422,78.83500022888184,,4.89052093890188,-3.253631669449667,,55.14824590311058,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-10-19,75.30000305175781,76.4000015258789,71.5,72.0,189217,0.0,0.0,75.96999969482422,78.6025001525879,,-5.225746624683345,-3.3491306926030355,,39.63848444812226,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-10-20,71.0999984741211,72.5,69.4000015258789,69.80000305175781,57752,0.0,0.0,75.43000030517578,78.2275001525879,,-7.463870118838718,-3.5761079440802845,,36.59085120511496,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-10-21,70.5,71.19999694824219,68.5,68.5,51125,0.0,0.0,74.65,77.9150001525879,,-8.238446081714676,-4.190464154776033,,34.884062749188146,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-10-24,71.19999694824219,71.19999694824219,68.0,68.69999694824219,37911,0.0,0.0,73.97999954223633,77.63250007629395,,-7.137067621877594,-4.704860117177856,,35.383423962053314,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-10-25,68.69999694824219,69.9000015258789,67.4000015258789,68.5999984741211,27565,0.0,0.0,73.39999923706054,77.37749996185303,,-6.539510644185224,-5.140384125557678,,35.23791411287313,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-10-26,68.5,70.19999694824219,68.0,69.5,14123,0.0,0.0,72.83999938964844,77.125,,-4.58539184189381,-5.5559165126114225,,37.720323684648406,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-10-27,68.80000305175781,72.30000305175781,68.80000305175781,71.80000305175781,23547,0.0,0.0,72.45,77.04500007629395,,-0.8971662501617534,-5.964047078647201,,43.663422093105915,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-10-28,71.80000305175781,73.4000015258789,70.0999984741211,71.5,11175,0.0,0.0,71.7900001525879,76.88500003814697,,-0.40395619441636055,-6.626780104092034,,43.08588020530739,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-10-31,72.0,72.0,69.5,70.80000305175781,23169,0.0,0.0,71.12000045776367,76.78500003814698,,-0.44994010678598334,-7.377742498624632,,41.69990351774082,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-11-01,70.80000305175781,71.9000015258789,69.5,69.80000305175781,18462,0.0,0.0,70.10000076293946,76.62500019073487,,-0.4279567873275251,-8.515496785061515,,39.73352729873552,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-11-02,70.9000015258789,70.9000015258789,69.30000305175781,69.69999694824219,24409,0.0,0.0,69.87000045776367,76.43750019073487,,-0.24331402376939387,-8.591986546633898,,39.532756820298935,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-11-03,72.69999694824219,72.80000305175781,69.9000015258789,71.0,55877,0.0,0.0,69.9900001525879,76.20000019073487,,1.4430630735964625,-8.149606328875107,,43.52744357810711,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-11-04,71.0,71.9000015258789,70.5999984741211,71.30000305175781,11798,0.0,0.0,70.27000045776367,75.90250034332276,,1.4657785502836755,-7.420704008540061,,44.43965081189026,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-11-07,71.30000305175781,71.9000015258789,69.80000305175781,70.5,29193,0.0,0.0,70.45000076293945,75.69250030517578,,0.0709712370746335,-6.926048843808445,,42.46956765430576,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-11-08,71.5999984741211,71.5999984741211,70.0,70.0999984741211,27639,0.0,0.0,70.60000076293946,75.45250034332275,,-0.7082185317494142,-6.43119785070545,,41.47941706009035,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-11-09,70.0999984741211,70.9000015258789,69.0,69.5,24165,0.0,0.0,70.60000076293946,75.16500034332276,,-1.5580747182043795,-6.073304808796998,,39.97394197819762,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-11-10,69.5,71.0999984741211,68.80000305175781,70.0,37016,0.0,0.0,70.42000045776368,74.72500038146973,,-0.5964221173437572,-5.761123990269796,,41.867440261324184,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-11-11,72.80000305175781,75.0,70.0,70.0999984741211,143780,0.0,0.0,70.28000030517578,74.27750034332276,,-0.25612098786719206,-5.381845134354121,,42.259734491608306,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-11-14,70.0999984741211,71.0999984741211,69.80000305175781,70.0,23450,0.0,0.0,70.2,73.99250030517578,,-0.28490028490028896,-5.125519869627237,,41.9548332751143,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-11-15,70.30000305175781,70.80000305175781,69.0999984741211,69.69999694824219,22318,0.0,0.0,70.18999938964843,73.72250022888184,,-0.6981086275354953,-4.791618336689969,,40.999127973044295,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-11-16,69.9000015258789,70.5,68.9000015258789,69.5,13354,0.0,0.0,70.16999969482421,73.45000019073487,,-0.9548235681033252,-4.465623536273866,,40.33941657410568,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-11-17,69.0,70.0999984741211,67.5,67.80000305175781,27949,0.0,0.0,69.85,73.2075002670288,,-2.9348560461591724,-4.58627907629973,,35.16044852834604,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-11-18,67.5,68.4000015258789,65.0,68.4000015258789,23255,0.0,0.0,69.55999984741212,72.91750030517578,,-1.667622662561528,-4.604519414011431,,38.177262547091885,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-11-21,68.5,68.5,66.0,67.0,15593,0.0,0.0,69.2099998474121,72.67250022888183,,-3.19317996284426,-4.764526293391019,,34.180980775345375,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-11-22,67.9000015258789,68.0,65.80000305175781,65.80000305175781,22939,0.0,0.0,68.78000030517578,72.37000026702881,,-4.332650829013903,-4.960618970024536,,31.16926366621489,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-11-23,65.80000305175781,66.80000305175781,65.5,66.5,17596,0.0,0.0,68.48000030517578,72.07250022888184,,-2.8913555729440152,-4.984564032463555,,34.77933329585154,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-11-24,66.9000015258789,68.69999694824219,65.5999984741211,67.4000015258789,15017,0.0,0.0,68.22000045776367,71.76000022888184,,-1.2019919765207943,-4.933110033203969,,39.19507538728787,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-11-25,67.4000015258789,69.4000015258789,67.0,69.0,14629,0.0,0.0,68.11000061035156,71.5200002670288,,1.306708826417442,-4.767896593883649,,46.172336850550664,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-11-28,70.0,70.0,68.0999984741211,69.69999694824219,9357,0.0,0.0,68.08000030517579,71.34000015258789,,2.3795485249773716,-4.569666162656779,,48.93320765637499,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-11-29,71.0,71.0999984741211,69.80000305175781,69.80000305175781,8549,0.0,0.0,68.09000091552734,71.16250019073486,,2.5113850980144727,-4.317581966586876,,49.33304230791289,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-11-30,69.80000305175781,70.30000305175781,68.19999694824219,70.0999984741211,22521,0.0,0.0,68.15000076293946,71.0400001525879,,2.86133189926839,-4.068129762726582,,50.58298798025079,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-12-01,71.0,72.0999984741211,69.9000015258789,70.9000015258789,17899,0.0,0.0,68.46000061035156,70.93250026702881,,3.564126342059084,-3.485707746617437,,53.852452538022085,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-12-02,70.5999984741211,71.5999984741211,69.5999984741211,69.9000015258789,10148,0.0,0.0,68.61000061035156,70.77250022888184,,1.8801937094469496,-3.0555648190139437,,49.4484657049699,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-12-05,69.9000015258789,71.0,68.9000015258789,70.4000015258789,18246,0.0,0.0,68.95000076293945,70.64750022888184,,2.1029742522045436,-2.402773573647862,,51.58060028510856,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-12-06,70.4000015258789,71.5999984741211,68.5,70.0999984741211,70705,0.0,0.0,69.38000030517578,70.5400001525879,,1.0377604003723209,-1.6444568257766763,,50.21214872048056,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-12-07,70.0999984741211,70.0999984741211,68.0999984741211,69.19999694824219,24010,0.0,0.0,69.65,70.39250011444092,,-0.6460919623227827,-1.054800033006062,,46.24809826142629,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-12-08,72.0999984741211,81.4000015258789,72.0,76.0,184946,0.0,0.0,70.5099998474121,70.40000019073486,,7.786129860258953,0.15624951190230654,,67.27161863029187,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-12-09,79.80000305175781,79.80000305175781,74.4000015258789,76.5,81621,0.0,0.0,71.2599998474121,70.36000022888183,74.30166689554851,7.353354145113984,1.2791353263254195,-5.3049505231259175,68.254803541792,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-12-12,77.0,79.5,76.19999694824219,78.30000305175781,86198,0.0,0.0,72.12000045776367,70.38000030517578,74.44750026067098,8.569055123083922,2.472293471217734,-5.463581639750458,71.56635245396322,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-12-13,78.5999984741211,89.0,78.5999984741211,86.30000305175781,144924,0.0,0.0,73.77000045776367,70.53750038146973,74.6483336130778,16.98522775686856,4.582668876572675,-5.50693234883931,81.0352832792347,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-12-14,86.30000305175781,89.0999984741211,86.30000305175781,89.0,81660,0.0,0.0,75.66000061035156,70.96250038146972,74.88333361943563,17.631508435149687,6.619693787042041,-5.2359223988237,83.08291508587166,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-12-15,82.69999694824219,82.69999694824219,76.0,79.5,191633,0.0,0.0,76.52000045776367,71.20500030517579,75.03666696548461,3.8944060695362674,7.464363639924801,-5.10639240155925,58.96085893539909,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-12-16,79.4000015258789,80.9000015258789,76.30000305175781,80.30000305175781,47005,0.0,0.0,77.56000061035157,71.50000038146973,75.2216670036316,3.5327519595719963,8.475524750419961,-4.94759923624424,60.013708796793416,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-12-19,82.0999984741211,85.80000305175781,80.30000305175781,83.5,60022,0.0,0.0,78.87000045776367,71.87000045776367,75.41000032424927,5.870419063476212,9.73980792460651,-4.694337423769058,63.99293401395569,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-12-20,84.0,84.0,80.0,80.9000015258789,30756,0.0,0.0,79.95000076293945,72.17750053405761,75.60500033696492,1.1882435945889605,10.768591557440137,-4.533430047789481,58.867059710170395,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-12-21,80.9000015258789,82.0999984741211,78.4000015258789,78.4000015258789,15408,0.0,0.0,80.87000122070313,72.40000057220459,75.79000034332276,-3.054284230914407,11.698895830879726,-4.472885282704494,54.35833543095156,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-12-22,78.0999984741211,80.5,75.69999694824219,76.4000015258789,58739,0.0,0.0,80.91000137329101,72.51500053405762,75.86916700998943,-5.57409438989441,11.57691619307176,-4.4209876134400865,50.993449144716145,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-12-23,76.5,80.0,76.0,76.69999694824219,28939,0.0,0.0,80.93000106811523,72.64500045776367,75.94583365122477,-5.226744178976144,11.4047774219074,-4.3462992435107335,51.47863327124067,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-12-27,77.9000015258789,78.80000305175781,75.5999984741211,76.9000015258789,26132,0.0,0.0,80.79000091552734,72.7975004196167,76.02833366394043,-4.8149515355443,10.979086438188904,-4.249512107689517,51.821100730150015,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-12-28,76.4000015258789,78.0,72.5999984741211,72.80000305175781,49939,0.0,0.0,79.44000091552735,72.8725004196167,76.08250033060709,-8.358506781527092,9.012316660047981,-4.2191041264965445,44.8350409248285,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-12-29,73.0,78.9000015258789,72.5,78.30000305175781,202312,0.0,0.0,78.37000122070313,73.08750057220459,76.18333371480306,-0.0893175550019344,7.227638935716311,-4.0636619476221725,53.82740058011732,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2022-12-30,78.30000305175781,83.0999984741211,78.0,82.0999984741211,51065,0.0,0.0,78.63000106811523,73.36500053405761,76.35916703542074,4.41307053143734,7.17644721015642,-3.921161816726236,58.82179510377274,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-01-02,82.30000305175781,85.0,80.5999984741211,80.69999694824219,30487,0.0,0.0,78.67000045776368,73.60000038146973,76.51166699727376,2.5803946595479856,6.888587024478365,-3.8055197724391294,56.40122761223283,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-01-03,78.9000015258789,83.69999694824219,78.0,79.0999984741211,29053,0.0,0.0,78.23000030517578,73.81500034332275,76.64250030517579,1.1121029854933482,5.981169059565553,-3.689206315809729,53.68237070161003,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-01-04,78.30000305175781,81.69999694824219,77.9000015258789,78.30000305175781,18119,0.0,0.0,77.97000045776367,74.02000045776367,76.75416698455811,0.4232430320080607,5.336395535763202,-3.562238552265854,52.324204111122185,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-01-05,78.30000305175781,80.0999984741211,76.5999984741211,76.9000015258789,11633,0.0,0.0,77.82000045776367,74.20500049591064,76.83000030517579,-1.1822139892996872,4.871639293435823,-3.416633865467147,49.942868903428,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-01-09,77.0,80.80000305175781,76.9000015258789,77.5999984741211,18801,0.0,0.0,77.94000015258788,74.39500045776367,76.90166695912679,-0.43623515242641675,4.765104742269366,-3.2595736873888654,51.140220575160264,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-01-10,77.9000015258789,79.80000305175781,77.0,78.9000015258789,28612,0.0,0.0,78.16000061035156,74.61500053405761,76.95083363850911,0.9467770083785546,4.751055486055849,-3.035487718592507,53.370941909161225,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-01-11,78.9000015258789,80.5,76.0,76.5,56165,0.0,0.0,78.12000045776367,74.77750053405762,76.9825003306071,-2.073733292717446,4.4699273174872864,-2.8642870614489477,48.92957088279,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-01-12,76.80000305175781,77.9000015258789,76.0,76.5999984741211,28389,0.0,0.0,78.5,74.95000057220459,77.00416698455811,-2.4203841093998806,4.736490194386923,-2.6676042255810035,49.119560374753505,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-01-13,76.5999984741211,77.69999694824219,75.80000305175781,76.5999984741211,35045,0.0,0.0,78.32999954223632,75.12750053405762,77.02083365122478,-2.2086059979898187,4.262751968870458,-2.458209068134453,49.1195603747535,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-01-16,77.4000015258789,81.4000015258789,77.0,80.9000015258789,30485,0.0,0.0,78.2099998474121,75.45500049591064,77.02500031789144,3.4394600226505556,3.6511819407525916,-2.038299013958095,57.08197146572203,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-01-17,86.0,95.5999984741211,84.80000305175781,87.4000015258789,172988,0.0,0.0,78.88000030517578,75.93000049591065,77.06166699727376,10.801218544295663,3.8851571052261678,-1.4685206607367436,65.79569517254602,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-01-18,88.30000305175781,88.69999694824219,84.30000305175781,87.4000015258789,49529,0.0,0.0,79.71000061035156,76.44000053405762,77.09833367665608,9.647473161013483,4.277865062071789,-0.8538876408917722,65.79569517254603,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-01-19,86.80000305175781,87.19999694824219,82.5999984741211,84.0999984741211,38234,0.0,0.0,80.2900001525879,76.8975004196167,77.09916699727377,4.74529619416173,4.4117165245409655,-0.2615677775924553,58.76998901050521,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-01-20,84.0,86.30000305175781,83.30000305175781,86.0999984741211,18122,0.0,0.0,81.2099998474121,77.38750038146972,77.07250029246012,6.021424253043901,4.939427487772528,0.4087062023605026,61.45624190731577,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-01-23,86.30000305175781,98.5,86.19999694824219,96.4000015258789,89441,0.0,0.0,83.09000015258789,78.11250038146973,77.14333362579346,16.018776445839816,6.372219230993853,1.2563195160550091,71.68706161164454,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-01-24,97.0,99.30000305175781,93.9000015258789,98.5999984741211,67873,0.0,0.0,85.05999984741212,78.85250034332276,77.22500025431314,15.918173819654577,7.872292542483731,2.1074782565879198,73.31625473638182,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-01-25,98.9000015258789,104.0,98.0,103.80000305175781,87590,0.0,0.0,87.7900001525879,79.70500049591064,77.34666697184245,18.236704489512377,10.143654232951251,3.0490435029692,76.72533615078481,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-01-26,104.0,105.0,97.0,97.69999694824219,71077,0.0,0.0,89.9,80.40250034332276,77.4516669591268,8.676303613172616,11.812443165476749,3.8099030015108513,66.06283648262188,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-01-27,97.69999694824219,102.80000305175781,97.0,101.19999694824219,29792,0.0,0.0,92.35999984741211,81.18000030517578,77.58916695912679,9.571239839145331,13.77186437571808,4.62800863417004,68.74657561145264,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-01-30,101.4000015258789,101.5999984741211,97.19999694824219,97.19999694824219,36510,0.0,0.0,93.98999938964843,81.83750019073486,77.66666692097982,3.4152543668888335,14.84954839846074,5.370171574375085,62.64902128528888,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-01-31,97.5,101.0,97.4000015258789,100.0,43436,0.0,0.0,95.24999923706055,82.59000015258789,77.77416693369547,4.986877481350453,15.328731155203865,6.192073034993801,64.98991133523937,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-02-01,99.9000015258789,104.80000305175781,98.30000305175781,101.80000305175781,45735,0.0,0.0,96.68999938964843,83.37500019073487,77.8983336130778,5.2849350443335,15.970013995146248,7.0305311084827,66.4457909192275,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-02-02,103.5999984741211,104.19999694824219,98.5,99.9000015258789,48557,0.0,0.0,98.26999969482422,84.12000026702881,78.0233336130778,1.658697299396181,16.82120706476217,7.81390177992745,63.446587613545354,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-02-03,100.0,102.0,98.0,101.5999984741211,21099,0.0,0.0,99.81999969482422,84.93000030517578,78.15083357493083,1.7832085601470604,17.532084465023857,8.674465031451142,64.97013433869758,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-02-06,102.4000015258789,103.19999694824219,97.30000305175781,99.5,36060,0.0,0.0,100.12999954223633,85.51750030517579,78.27583357493083,-0.6291816090247664,17.087144952687716,9.25147187773191,61.55694462422859,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-02-07,99.4000015258789,100.5999984741211,97.30000305175781,98.9000015258789,24541,0.0,0.0,100.15999984741211,86.07750034332275,78.41833356221517,-1.2579855465782115,16.360256104000317,9.767061391365825,60.577735285535454,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-02-08,98.0999984741211,103.0,98.0999984741211,100.5999984741211,38080,0.0,0.0,99.83999938964844,86.63500022888184,78.6016668955485,0.7612170363769566,15.24210668422715,10.220309123989187,62.40263329979967,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-02-09,100.80000305175781,103.19999694824219,98.5,100.5999984741211,28631,0.0,0.0,100.12999954223633,86.99250011444092,78.78833357493083,0.469388728686159,15.101875920927313,10.412920501367879,62.40263329979967,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-02-10,100.0,100.80000305175781,98.0999984741211,100.80000305175781,14295,0.0,0.0,100.09000015258789,87.28750019073486,78.95083357493083,0.7093644700644596,14.667048470717864,10.559314244468176,62.63861652864017,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-02-13,100.80000305175781,104.80000305175781,100.80000305175781,103.4000015258789,31670,0.0,0.0,100.71000061035156,87.88500022888184,79.10583356221517,2.6710365397921123,14.592934343823345,11.098001590188703,65.65639548577202,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-02-14,103.4000015258789,103.80000305175781,99.5,99.5,25924,0.0,0.0,100.66000061035156,88.3650001525879,79.26000022888184,-1.1523947976533877,13.913880423847413,11.487509333097702,58.07838232937218,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-02-15,99.80000305175781,100.80000305175781,98.5,98.69999694824219,24539,0.0,0.0,100.35,88.74500007629395,79.41583353678385,-1.644248183116898,13.076792961551911,11.747237451318837,56.6343731092408,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-02-16,98.5999984741211,98.5999984741211,93.4000015258789,94.5999984741211,30936,0.0,0.0,99.81999969482422,89.0875,79.54750016530355,-5.229414182189973,12.047144318590389,11.992834237244262,49.80051408315084,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-02-17,94.0,94.0999984741211,89.5,90.69999694824219,48486,0.0,0.0,98.72999954223633,89.39499988555909,79.64000015258789,-8.133295483870569,10.44241810909742,12.248869555852473,44.32190737407548,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-02-20,94.0999984741211,95.0,88.30000305175781,89.30000305175781,24984,0.0,0.0,97.7099998474121,89.71749992370606,79.75916684468588,-8.607099384697253,8.908518327531095,12.485502886974643,42.51384769938605,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-02-21,90.0,93.69999694824219,90.0,93.5,34917,0.0,0.0,97.16999969482421,90.1375,79.88916683197021,-3.776885567922562,7.8019688751343335,12.82818882012497,49.2080212383468,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-02-22,91.9000015258789,92.9000015258789,89.0,91.4000015258789,28621,0.0,0.0,96.25,90.5,80.02750015258789,-5.038959453632305,6.353591160220995,13.086126428345587,46.30458426695199,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-02-23,92.5999984741211,92.5999984741211,88.69999694824219,88.69999694824219,29728,0.0,0.0,95.05999984741212,90.8974998474121,80.13166681925456,-6.690514316619862,4.579333872755045,13.435179193814871,42.8073475852342,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-02-24,88.69999694824219,90.0,85.30000305175781,85.30000305175781,31818,0.0,0.0,93.5099998474121,91.0724998474121,80.19916687011718,-8.779806233612677,2.676439105200716,13.557912633811172,38.83022262680219,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-02-27,87.4000015258789,87.4000015258789,84.0999984741211,86.4000015258789,36506,0.0,0.0,91.80999984741212,91.17999992370605,80.2483335494995,-5.892602473068954,0.6909409127365784,13.62229705052202,40.74823257546571,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-02-28,86.4000015258789,86.5999984741211,84.0,84.69999694824219,16740,0.0,0.0,90.32999954223632,91.27999992370606,80.26083354949951,-6.232705217010069,-1.0407541435843202,13.729195034350926,38.72720251291626,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-03-01,84.69999694824219,86.9000015258789,83.19999694824219,83.69999694824219,22010,0.0,0.0,88.82999954223632,91.39499988555909,80.30083351135254,-5.775078937780422,-2.806499640608949,13.815754941868832,37.547481271247314,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-03-02,83.69999694824219,87.0,83.19999694824219,84.0999984741211,18552,0.0,0.0,87.77999954223633,91.53999977111816,80.33750019073486,-4.192300167812781,-4.107494252002561,13.944296939519738,38.35638659227797,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-03-03,84.0999984741211,86.5999984741211,83.80000305175781,85.19999694824219,15499,0.0,0.0,87.22999954223633,91.74749965667725,80.37250016530355,-2.3271840016589973,-4.923840029805263,14.152850126571323,40.63359916068885,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-03-06,85.30000305175781,90.9000015258789,85.30000305175781,87.69999694824219,37128,0.0,0.0,87.06999893188477,91.99999961853027,80.37333348592122,0.723553490393711,-5.358696420747069,14.465825452723891,45.55621976905012,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-03-07,87.30000305175781,89.0,83.4000015258789,85.0999984741211,38612,0.0,0.0,86.22999877929688,92.15499954223633,80.3491668065389,-1.3104491721819298,-6.429386134632783,14.693161366717058,41.68495601951281,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-03-08,86.19999694824219,86.19999694824219,85.0,85.5,20335,0.0,0.0,85.63999862670899,92.37999954223633,80.38333346048991,-0.16347341073558252,-7.295952531852745,14.924320210784787,42.49458686869873,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-03-09,85.5,85.5,82.5999984741211,83.5999984741211,27537,0.0,0.0,85.12999877929687,92.55499954223633,80.40916678110759,-1.797251647027937,-8.022257900342979,15.105034969697574,39.67672777234776,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-03-10,82.5999984741211,83.80000305175781,80.69999694824219,83.0,31263,0.0,0.0,84.89999847412109,92.7149995803833,80.43083343505859,-2.2379252158646876,-8.429058018262364,15.272956428137963,38.80170895063424,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-03-13,82.69999694824219,82.9000015258789,78.5,81.9000015258789,44986,0.0,0.0,84.44999847412109,92.7399995803833,80.46750011444092,-3.0195346291493474,-8.938970394405459,15.251498367028201,37.182700571034296,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-03-14,82.5999984741211,85.0,81.9000015258789,84.30000305175781,20487,0.0,0.0,84.40999908447266,92.66249961853028,80.50333347320557,-0.13031161462846233,-8.905976601139859,15.103928770069771,42.791417812683484,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-03-15,83.69999694824219,85.5999984741211,80.5,81.30000305175781,31615,0.0,0.0,84.16999969482421,92.50999965667725,80.54083347320557,-3.4097619739481626,-9.015241587725017,14.860991210692653,38.200044804162545,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-03-16,84.0999984741211,84.0999984741211,80.5,82.69999694824219,16093,0.0,0.0,84.02999954223633,92.47499961853028,80.5808334350586,-1.5827711546346415,-9.132198011495563,14.760540039657673,41.361992462241254,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-03-17,84.5999984741211,86.5,83.0999984741211,83.19999694824219,19103,0.0,0.0,83.82999954223632,92.4024995803833,80.62083339691162,-0.7515240336804712,-9.277346475556698,14.613674514462428,42.49363938058931,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-03-20,82.5,82.5,79.0,80.9000015258789,45587,0.0,0.0,83.15,92.0149995803833,80.62916673024496,-2.705951261721106,-9.634298343542273,14.121233434336586,38.78560337291888,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-03-21,81.19999694824219,84.0999984741211,80.0,80.19999694824219,31865,0.0,0.0,82.65999984741211,91.55499954223633,80.64250005086264,-2.976049968196242,-9.71547128971451,13.531945914984023,37.707147725469675,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-03-22,80.19999694824219,82.0,78.9000015258789,80.0,25271,0.0,0.0,82.10999984741211,90.95999946594239,80.6683333714803,-2.569723360532455,-9.729551088931052,12.758000152387716,37.38728558107869,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-03-23,79.5999984741211,81.5,79.5,79.5,27355,0.0,0.0,81.7,90.50499954223633,80.69000002543132,-2.692778457772341,-9.72874381169105,12.163836304017343,36.552476269096864,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-03-24,80.0,82.5,79.5,80.69999694824219,28937,0.0,0.0,81.46999969482422,89.99249954223633,80.7375,-0.9451365526775067,-9.470233509196206,11.463074212399857,40.01430716381977,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-03-27,80.69999694824219,82.30000305175781,79.69999694824219,80.5999984741211,9705,0.0,0.0,81.33999938964844,89.5774995803833,80.78250001271566,-0.9097626273421403,-9.195947899107026,10.887258461032102,39.819330318514716,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-03-28,80.4000015258789,81.0,78.5,79.19999694824219,23484,0.0,0.0,80.82999877929687,89.05749950408935,80.8066666285197,-2.01658029898694,-9.238414249902318,10.210584373564085,37.09416322844193,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-03-29,79.5,82.9000015258789,79.4000015258789,82.9000015258789,19072,0.0,0.0,80.98999862670898,88.58499946594239,80.8691666285197,2.3583194611143523,-8.57368728906907,9.54113064236969,47.34970145383957,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-03-30,85.5,85.9000015258789,83.5999984741211,84.0999984741211,22608,0.0,0.0,81.12999877929687,88.18999938964843,80.94999993642172,3.660791001493424,-8.005443541459254,8.943791796063033,50.18618260516716,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-03-31,84.0999984741211,86.30000305175781,82.80000305175781,85.9000015258789,9978,0.0,0.0,81.39999923706054,87.79749946594238,81.03999996185303,5.528258391886523,-7.28665425302175,8.338474219237694,54.17428328120498,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-04-03,87.5999984741211,90.4000015258789,85.5,89.5999984741211,52684,0.0,0.0,82.26999893188477,87.54999942779541,81.15583330790201,8.909687173212651,-6.030840126121514,7.878874332587019,61.073158142025754,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-04-04,90.0999984741211,99.0,89.9000015258789,94.69999694824219,92164,0.0,0.0,83.71999893188476,87.44499931335449,81.29416662851969,13.115143521789625,-4.259820928263017,7.5661427380657305,68.18328972660065,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-04-05,96.5,96.5,91.5,94.69999694824219,29153,0.0,0.0,85.18999862670898,87.29749927520751,81.43749993642172,11.16328028505403,-2.4141592439602215,7.195701419322427,68.18328972660065,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-04-06,94.69999694824219,101.0,94.69999694824219,98.0999984741211,30954,0.0,0.0,87.0499984741211,87.23499927520751,81.5883332570394,12.693854329342724,-0.21207176319538884,6.92092336336694,72.12052598444048,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-04-11,98.0999984741211,102.0,98.0999984741211,100.4000015258789,48882,0.0,0.0,89.01999893188477,87.22499923706054,81.82499993642172,12.78364719224693,2.057895913470596,6.599449196253763,74.42604195350573,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-04-12,101.5999984741211,104.0,99.4000015258789,99.69999694824219,28393,0.0,0.0,90.92999877929688,87.13249912261963,82.07416655222575,9.6447798159897,4.358304530360261,6.163123894989721,72.46199882800738,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-04-13,99.69999694824219,104.19999694824219,99.69999694824219,102.0,73087,0.0,0.0,93.20999908447266,87.19499912261963,82.35333321889242,9.430319710186138,6.8983313520014065,5.879137752516018,74.81380176803552,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-04-14,104.0,104.19999694824219,98.4000015258789,98.4000015258789,39541,0.0,0.0,94.75999908447265,87.18749923706055,82.60083325703938,3.841285855397082,8.68530456048828,5.55280836665202,65.39924578031241,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-04-17,98.4000015258789,100.5999984741211,95.0,97.0,34396,0.0,0.0,96.04999923706055,87.24749927520752,82.83749993642171,0.9890689958203547,10.089114341360123,5.323675077314635,62.125113735187625,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-04-18,95.5,98.0,92.30000305175781,92.9000015258789,41644,0.0,0.0,96.74999923706055,87.30249938964843,83.03249994913737,-3.9793258310506356,10.821568584475509,5.14256398774781,53.6535803248908,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-04-19,91.4000015258789,94.5,91.4000015258789,93.30000305175781,21589,0.0,0.0,97.11999969482422,87.40249938964844,83.21166661580403,-3.933274974330525,11.118103455891186,5.036352406200285,54.3082099272884,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-04-20,93.30000305175781,94.5,91.5999984741211,93.9000015258789,23152,0.0,0.0,97.0400001525879,87.41249942779541,83.39833329518636,-3.2357776399130076,11.013871915131547,4.813245030210623,55.327488743954724,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-04-21,93.9000015258789,94.5999984741211,92.5999984741211,94.5999984741211,22911,0.0,0.0,97.03000030517578,87.49249935150146,83.59666659037272,-2.504381967857276,10.900935536607959,4.660272855398043,56.54541533661325,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-04-24,94.69999694824219,94.69999694824219,91.5,91.5,17446,0.0,0.0,96.37000045776367,87.56249942779542,83.77749989827474,-5.053440318180816,10.058530863695788,4.517918933026816,50.03903179212431,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-04-25,95.5,98.0,92.5999984741211,94.0,70289,0.0,0.0,95.73000030517578,87.77999935150146,83.97999992370606,-1.8071663007006629,9.056733894289252,4.524886200580629,54.578138601647545,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-04-26,95.0,95.0,89.69999694824219,90.30000305175781,45689,0.0,0.0,94.79000091552734,87.87749938964843,84.14083328247071,-4.736784281467429,7.866065345383701,4.440966367225407,47.674587544659055,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-04-27,90.4000015258789,94.5,90.4000015258789,91.0999984741211,27748,0.0,0.0,93.70000076293945,88.03749942779541,84.30583324432374,-2.7748156538401236,6.431919775036528,4.426343990524434,49.17161897184413,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-04-28,91.0999984741211,94.19999694824219,90.19999694824219,93.19999694824219,31241,0.0,0.0,93.18000030517578,88.27499942779541,84.49499988555908,0.02146023073719127,5.556500605125942,4.4736369576377255,52.97494641363776,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-05-02,92.69999694824219,93.0,88.0999984741211,88.19999694824219,50081,0.0,0.0,92.3,88.37749938964843,84.64583320617676,-4.442040142749523,4.438347585574481,4.408564535459457,44.447145986989476,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-05-03,88.19999694824219,88.69999694824219,86.0,87.30000305175781,28428,0.0,0.0,91.7400001525879,88.42999954223633,84.7941665649414,-4.839761383742308,3.743074327135587,4.287833850587287,43.10215393215817,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-05-04,87.9000015258789,89.9000015258789,86.19999694824219,86.9000015258789,17586,0.0,0.0,91.1,88.40999965667724,84.9349999109904,-4.610316656554433,3.0426426351870104,4.091363689089952,42.48678373023691,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-05-05,86.9000015258789,89.9000015258789,85.9000015258789,88.4000015258789,13726,0.0,0.0,90.55,88.4924997329712,85.08749993642171,-2.3743771111221323,2.3250561044578575,4.001762655024231,45.62205125755484,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-05-08,88.4000015258789,90.0,88.4000015258789,89.9000015258789,11341,0.0,0.0,90.08000030517579,88.60249977111816,85.2533332824707,-0.19982102429737492,1.667560777488637,3.9284874381986086,48.6374071124767,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-05-09,92.0,92.0,86.4000015258789,86.4000015258789,11632,0.0,0.0,89.57000045776367,88.67249984741211,85.39249998728434,-3.5391301950250207,1.0121521462640373,3.841086583266907,42.68908995301119,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-05-10,87.5,87.5,85.0999984741211,85.0999984741211,23114,0.0,0.0,88.68000030517578,88.72499980926514,85.52249997456869,-4.036988970156489,-0.05071795343600785,3.7446284143339605,40.69814467058906,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-05-11,85.0999984741211,86.9000015258789,83.19999694824219,83.69999694824219,23030,0.0,0.0,88.01999969482422,88.76999969482422,85.65499992370606,-4.907978597546007,-0.8448800299407111,3.6366817744355053,38.60976979122123,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-05-12,85.0999984741211,85.0999984741211,82.9000015258789,84.0999984741211,13135,0.0,0.0,87.31999969482422,88.7649995803833,85.78583323160807,-3.687587301828617,-1.62789375586098,3.47279525831726,39.563987504093014,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-05-15,84.0999984741211,86.0999984741211,84.0999984741211,84.9000015258789,16239,0.0,0.0,86.4900001525879,88.85499954223633,85.9349999109904,-1.838361225464069,-2.6616390769595957,3.3979166047249683,41.52173802237895,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-05-16,84.9000015258789,84.9000015258789,82.5999984741211,83.0999984741211,22093,0.0,0.0,85.98000030517578,88.8649995803833,86.0791665395101,-3.349618307551129,-3.246496695921186,3.2363615412034807,38.499795181987835,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-05-17,83.0999984741211,85.5,82.30000305175781,82.30000305175781,20112,0.0,0.0,85.48000030517578,88.84249973297119,86.21083323160808,-3.72016523404881,-3.7847870533831047,3.0525937434023636,37.20381851483924,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-05-19,84.9000015258789,84.9000015258789,81.19999694824219,82.80000305175781,25930,0.0,0.0,85.07000045776367,88.88999977111817,86.33916657765707,-2.6683876734347565,-4.297445520520387,2.9544334217852053,38.595081116980246,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-05-22,80.5999984741211,82.0999984741211,80.0,81.30000305175781,23405,0.0,0.0,84.36000061035156,88.91749992370606,86.44166660308838,-3.6273086017714737,-5.125536949717404,2.864166573726408,36.01704004446698,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-05-23,75.0,78.0,73.0,73.9000015258789,474461,0.0,0.0,82.76000061035157,88.76499996185302,86.47666664123535,-10.705653720554057,-6.765053066053193,2.6461858550945845,26.583170209803725,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-05-24,74.0,75.5999984741211,71.5999984741211,71.69999694824219,237996,0.0,0.0,81.2900001525879,88.56999988555908,86.49249992370605,-11.797272956506944,-8.219487120218638,2.4019423229592998,24.52637224039296,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-05-25,72.0999984741211,75.0,72.0,74.19999694824219,120695,0.0,0.0,80.2,88.40749988555908,86.52666657765707,-7.481300563289047,-9.28371449954296,2.1737036480123435,31.0545446361524,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-05-26,74.80000305175781,79.80000305175781,74.5,79.69999694824219,182870,0.0,0.0,79.8,88.3849998474121,86.59999987284343,-0.1253171074659269,-9.713186470818865,2.0612008974476095,42.78049048146878,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-05-29,80.5999984741211,81.5,76.19999694824219,77.5999984741211,67311,0.0,0.0,79.15,88.34499988555908,86.66416651407877,-1.95830893983438,-10.408059196864734,1.9394790708651761,39.98426415190322,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-05-30,77.69999694824219,79.5,77.5,78.4000015258789,67664,0.0,0.0,78.5,88.23249988555908,86.73083318074545,-0.1273865912370621,-11.030515850942118,1.7314104450999384,41.551580561549244,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-05-31,78.0,84.5,75.0,81.4000015258789,149177,0.0,0.0,78.33000030517579,88.16499996185303,86.82499987284342,3.919317258703322,-11.155219940943253,1.5433343978946823,47.12772294088973,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-06-01,80.4000015258789,81.5,78.4000015258789,80.5999984741211,50702,0.0,0.0,78.15999984741211,88.03249988555908,86.91999988555908,3.1217996820272167,-11.214608299186175,1.279912564961736,45.870958257516364,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-06-02,80.5999984741211,80.9000015258789,77.80000305175781,78.30000305175781,56086,0.0,0.0,77.7099998474121,87.75,86.93916657765706,0.7592371708971947,-11.441595615484779,0.932644576962529,42.372463428839445,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-06-05,78.5,80.0,76.0,77.0,56589,0.0,0.0,77.27999954223633,87.30750007629395,86.94333324432372,-0.36231825038158205,-11.485268190355994,0.41885538359434676,40.492621214673164,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-06-07,77.0,79.5,76.19999694824219,78.9000015258789,113904,0.0,0.0,77.77999954223633,86.91250019073486,86.94833323160807,1.4399614171177697,-10.507695243442194,-0.04121187783757089,44.376705568288656,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-06-08,78.9000015258789,79.9000015258789,76.5,76.5,53601,0.0,0.0,78.2599998474121,86.37250022888183,86.86666653951009,-2.2489136862300967,-9.392457506697271,-0.5688790997908206,40.75784923200857,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-06-09,76.5999984741211,77.5999984741211,76.0,76.5999984741211,62410,0.0,0.0,78.5,85.77750015258789,86.7633331934611,-2.4203841093998806,-8.484159761758143,-1.1362323283212685,40.97383611774503,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-06-12,76.80000305175781,81.19999694824219,76.19999694824219,80.69999694824219,183470,0.0,0.0,78.6,85.3025001525879,86.77333316802978,2.67175184254732,-7.857331427096,-1.6950288317192217,49.158322691878816,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-06-13,80.9000015258789,81.5,80.30000305175781,81.0,49789,0.0,0.0,78.94000015258788,84.77750015258789,86.7791664759318,2.6095766955031885,-6.885671303698865,-2.306620822290421,49.70783055625796,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-06-14,82.0,82.0999984741211,78.69999694824219,79.0,82221,0.0,0.0,79.0,84.29250011444091,86.74166647593181,0.0,-6.278731924258356,-2.8235177637156252,46.12841913066219,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-06-15,79.0,80.5999984741211,77.9000015258789,79.5999984741211,35368,0.0,0.0,78.81999969482422,83.85750007629395,86.73083311716715,0.9895950042081696,-6.007215069476893,-3.312931442721804,47.35321441161251,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-06-16,79.5999984741211,80.0999984741211,78.5,78.9000015258789,41315,0.0,0.0,78.65,83.50750007629395,86.73499978383383,0.3178658943151946,-5.816842884598445,-3.721104185834606,46.03813437665447,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-06-19,78.30000305175781,78.30000305175781,76.5999984741211,76.9000015258789,36175,0.0,0.0,78.5099998474121,83.09750003814698,86.73916645050049,-2.050692045169157,-5.520623591117568,-4.198410661960543,42.41379863294502,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-06-20,77.4000015258789,77.4000015258789,75.30000305175781,75.69999694824219,70283,0.0,0.0,78.37999954223633,82.64249992370605,86.73083311716715,-3.4192429314189825,-5.157758278615456,-4.713817504713751,40.36071272007391,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-06-21,76.0,80.4000015258789,76.0,77.19999694824219,147650,0.0,0.0,78.20999908447266,82.20749988555909,86.73333307902018,-1.291397708801391,-4.862695990817559,-5.21810131444821,44.009174989854635,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-06-22,77.0,78.0999984741211,75.69999694824219,77.80000305175781,41133,0.0,0.0,78.33999938964844,81.86499996185303,86.77499974568686,-0.6892983687742803,-4.305870120133328,-5.658311493199257,45.44680360686943,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-06-26,78.4000015258789,78.4000015258789,75.9000015258789,76.19999694824219,32373,0.0,0.0,78.29999923706055,81.41999988555908,86.75749969482422,-2.6819952864372407,-3.8319831157994213,-6.152205662957302,42.32585754639174,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-06-27,76.19999694824219,76.80000305175781,73.0999984741211,73.5,49012,0.0,0.0,77.57999954223632,80.99999980926513,86.6858330408732,-5.259086834635875,-4.222222561829706,-6.559126251837652,37.62972562660078,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-06-28,75.0,77.5999984741211,74.0,76.30000305175781,82747,0.0,0.0,77.10999984741211,80.62999992370605,86.64916642506917,-1.0504432593141602,-4.365620835451624,-6.946594814121215,44.506102411601915,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-06-29,76.30000305175781,77.5999984741211,75.5999984741211,77.4000015258789,33887,0.0,0.0,76.95,80.23500003814698,86.63499978383382,0.5847973045859693,-4.094223264890824,-7.387314320604508,46.97922880672332,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-06-30,77.4000015258789,78.0,77.0999984741211,77.19999694824219,23377,0.0,0.0,76.7099998474121,79.96000003814697,86.62583306630452,0.6387656130944596,-4.064532502731828,-7.694971340772488,46.572817174518605,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-07-03,80.9000015258789,85.0999984741211,79.19999694824219,81.5999984741211,256614,0.0,0.0,76.97999954223633,79.81749992370605,86.66499970753988,6.0015574946190124,-3.554985290421226,-7.901113260187424,55.660421011387015,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-07-04,82.19999694824219,86.5999984741211,82.19999694824219,85.4000015258789,215205,0.0,0.0,77.82999954223632,79.77999992370606,86.7299997329712,9.726329215169196,-2.444222089915428,-8.013374646216022,61.71677713865013,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-07-05,85.4000015258789,89.0999984741211,83.30000305175781,83.30000305175781,123294,0.0,0.0,78.59000015258789,79.65249996185302,86.76666641235352,5.993132574150818,-1.3339189727553857,-8.199193013467672,57.076964684099636,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-07-06,84.30000305175781,84.30000305175781,80.80000305175781,81.19999694824219,82170,0.0,0.0,78.9900001525879,79.43499984741212,86.80583305358887,2.79781844712642,-0.5602060750034938,-8.491172709127083,52.80198825382416,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-07-07,81.5,82.80000305175781,80.80000305175781,81.30000305175781,58941,0.0,0.0,79.34000015258789,79.30749988555908,86.84499975840251,2.4703842896400485,0.040980067554400985,-8.679256023734574,52.982590101389995,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-07-10,81.30000305175781,81.5999984741211,79.4000015258789,80.30000305175781,44286,0.0,0.0,79.75000076293945,79.1875,86.8758331298828,0.6896580358077605,0.7103403478319814,-8.849794992340902,50.88580783305772,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-07-11,80.5999984741211,81.69999694824219,79.80000305175781,80.5,54834,0.0,0.0,80.45000076293945,79.10750007629395,86.87249978383382,0.06214945504833333,1.6970586674471508,-8.938386401751579,51.300904358758864,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-07-12,80.69999694824219,80.80000305175781,78.30000305175781,80.4000015258789,47165,0.0,0.0,80.86000061035156,79.01500015258789,86.8141664505005,-0.5688833551823742,2.335000258432889,-8.983748409724717,51.06849700948857,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-07-13,79.80000305175781,80.0999984741211,77.0,77.0999984741211,78377,0.0,0.0,80.83000030517579,78.82000007629395,86.72833309173583,-4.6146255313274445,2.5501144721342968,-9.118511486986543,43.98658208856013,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-07-14,77.0999984741211,77.9000015258789,75.80000305175781,75.9000015258789,73414,0.0,0.0,80.70000076293945,78.64000015258789,86.65999978383383,-5.947954388700442,2.6195328158118967,-9.254557640492916,41.72088609954949,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-07-17,76.0,78.19999694824219,75.5,77.19999694824219,36084,0.0,0.0,80.26000061035157,78.5125,86.5858331044515,-3.8126135544966786,2.2257610066569846,-9.324080874422437,45.024555157554545,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-07-18,77.19999694824219,77.19999694824219,75.5999984741211,76.0,36701,0.0,0.0,79.32000045776367,78.34249992370606,86.41583309173583,-4.185577960922357,1.2477270128085671,-9.342423580479085,42.62269612031293,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-07-19,76.0,76.69999694824219,75.5,76.0,25796,0.0,0.0,78.59000015258789,78.2099998474121,86.22749977111816,-3.2955848677430044,0.48587176309572383,-9.29807769561644,42.62269612031293,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-07-20,76.0,76.80000305175781,74.0999984741211,75.69999694824219,55901,0.0,0.0,78.0400001525879,78.25499973297119,85.99333305358887,-2.998466427178894,-0.27474229265469724,-8.998759608253993,41.973481964698806,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-07-21,74.69999694824219,77.80000305175781,74.69999694824219,77.5,66696,0.0,0.0,77.65999984741211,78.39999980926514,85.82499974568685,-0.20602607227205796,-0.9438775046598643,-8.651325322951553,47.17269672150458,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-07-24,77.5999984741211,77.69999694824219,76.4000015258789,76.9000015258789,57886,0.0,0.0,77.31999969482422,78.46749992370606,85.62249978383382,-0.5431947369412975,-1.4623891802307365,-8.356448221193698,45.70270549188414,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-07-25,64.80000305175781,73.0,58.79999923706055,70.0,889519,0.0,0.0,76.26999969482422,78.225,85.39583314259848,-8.220794178460855,-2.499201412816584,-8.397169836875115,32.976216856284395,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-07-26,69.5999984741211,70.69999694824219,65.9000015258789,70.19999694824219,213422,0.0,0.0,75.24999923706055,78.03999996185303,85.14749978383382,-6.710966564809268,-3.575090628083376,-8.347279532604938,33.55377519771578,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-07-27,71.5,74.0,68.0,73.0,127768,0.0,0.0,74.83999938964844,77.90499992370606,84.90749975840251,-2.458577504882959,-3.9342796188424805,-8.247210028114717,41.194034942710694,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-07-28,73.0,75.30000305175781,71.0999984741211,75.0,70168,0.0,0.0,74.74999923706055,77.74499988555908,84.69999974568685,0.33444918460347167,-3.852338610723756,-8.21133397994129,45.972706668525,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-07-31,75.0,75.4000015258789,73.5999984741211,75.0,53259,0.0,0.0,74.52999954223633,77.60499992370606,84.47833309173583,0.6306191609424664,-3.9623740538532135,-8.136208322867775,45.972706668525,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-08-01,73.9000015258789,74.69999694824219,72.30000305175781,72.30000305175781,35298,0.0,0.0,74.15999984741211,77.45499992370605,84.2516664505005,-2.508086299192736,-4.254083118636051,-8.067100406598621,40.78379693265071,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-08-02,71.5,72.5,71.0,71.5,35868,0.0,0.0,73.7099998474121,77.31749992370605,84.0233331044515,-2.9982361307652314,-4.6658260805816125,-7.980917839106973,39.36601149644571,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-08-03,71.0,71.69999694824219,70.19999694824219,70.5,40202,0.0,0.0,73.19000015258788,77.10749988555908,83.77249978383382,-3.6753656879078047,-5.080568996252562,-7.956071402277691,37.60616440329863,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-08-04,70.5,73.4000015258789,70.0999984741211,72.80000305175781,52023,0.0,0.0,72.72000045776367,77.01499996185302,83.54083315531413,0.11001456750623081,-5.576835040208714,-7.811549091602512,43.8262973450263,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-08-07,72.80000305175781,73.69999694824219,70.19999694824219,70.30000305175781,56536,0.0,0.0,72.06000061035157,76.85750007629395,83.28666648864746,-2.442405694818889,-6.242070664775796,-7.719322531932346,39.24641563326983,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-08-08,70.30000305175781,72.5,68.69999694824219,70.69999694824219,51332,0.0,0.0,72.13000030517578,76.60750007629395,83.01416645050048,-1.9825361858912742,-5.844727692013168,-7.717557915884984,40.320996448461294,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-08-09,71.0999984741211,72.19999694824219,70.9000015258789,71.0,18556,0.0,0.0,72.21000061035156,76.35750007629395,82.77666645050049,-1.67566902108307,-5.4316857699614856,-7.754801744819151,41.161588173008035,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-08-10,71.0,72.4000015258789,70.69999694824219,71.5,33261,0.0,0.0,72.06000061035157,76.17000007629395,82.54999980926513,-0.7771310097256926,-5.395824421459489,-7.728648997834542,42.61239849259684,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-08-11,71.5,73.0,71.0,71.5999984741211,25326,0.0,0.0,71.72000045776367,75.97000007629394,82.35833314259847,-0.16732010997859773,-5.594313037070088,-7.756753715794021,42.91556099549924,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-08-14,71.5999984741211,71.5999984741211,69.69999694824219,69.9000015258789,25900,0.0,0.0,71.21000061035156,75.74500007629395,82.18499984741212,-1.8396279641124176,-5.987193163079445,-7.835979537719684,39.13098172974771,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-08-15,69.69999694824219,69.69999694824219,67.0999984741211,67.69999694824219,39835,0.0,0.0,70.75,75.51499996185302,82.00499979654948,-4.310958377042844,-6.310004587512544,-7.914151394180652,34.84804765324492,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-08-16,67.69999694824219,67.69999694824219,65.0,65.19999694824219,68230,0.0,0.0,70.11999969482422,75.25249996185303,81.76916643778483,-7.016547016535697,-6.82037177453318,-7.969588978126728,30.73173099531178,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-08-17,64.9000015258789,64.9000015258789,62.5,63.79999923706055,57784,0.0,0.0,69.44999961853027,74.91750001907349,81.53916641871135,-8.135349766023932,-7.298028363401378,-8.12084141949033,28.68809283930544,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-08-18,63.79999923706055,63.79999923706055,61.5,63.099998474121094,63330,0.0,0.0,68.4799991607666,74.54999990463257,81.32583309809367,-7.856309510190239,-8.142187460269577,-8.331710768075643,27.696358121738925,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-08-21,63.099998474121094,64.5,62.5,63.599998474121094,22656,0.0,0.0,67.80999870300293,74.23499994277954,81.14499972661336,-6.208524272830285,-8.654948804107237,-8.515619948381776,29.569248404763798,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-08-22,63.599998474121094,65.0,62.900001525878906,62.900001525878906,35658,0.0,0.0,67.02999916076661,73.96999998092652,80.94916639328002,-6.161416808289375,-9.382183076854696,-8.621665575215708,28.457861560815047,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-08-23,64.0,65.80000305175781,62.5,65.30000305175781,41784,0.0,0.0,66.45999946594239,73.69499998092651,80.78749977747599,-1.7454053919741894,-9.817491711590556,-8.77920447604557,37.17647321228273,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-08-24,65.30000305175781,65.69999694824219,62.400001525878906,62.400001525878906,38622,0.0,0.0,65.54999961853028,73.31999998092651,80.60999981562297,-4.805489109050891,-10.597381839085546,-9.043542800360594,32.087879001788,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-08-25,62.400001525878906,64.0999984741211,62.0,63.29999923706055,17359,0.0,0.0,64.71999969482422,72.97250003814698,80.43666648864746,-2.1940674667173052,-11.30905524548109,-9.279557167568537,35.05871299801119,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-08-28,63.29999923706055,64.30000305175781,62.900001525878906,63.29999923706055,47688,0.0,0.0,64.05999946594238,72.51500005722046,80.25416650772095,-1.1863881286572464,-11.65965742895452,-9.643320449606732,35.0587129980112,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-08-29,44.0,44.400001525878906,35.25,36.0,1655163,0.0,0.0,60.88999977111816,71.28000001907348,79.82333319981893,-40.87699107353945,-14.576319086945999,-10.702801847874763,13.80840548654838,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-08-30,38.5,38.5,33.70000076293945,34.650001525878906,740535,0.0,0.0,57.83500022888184,70.06374998092652,79.40291655858358,-40.088179495544864,-17.453747130825448,-11.761742493131996,13.376617182377302,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-08-31,34.650001525878906,35.150001525878906,33.29999923706055,33.29999923706055,269301,0.0,0.0,54.785000228881835,68.86625003814697,78.96791655222574,-39.216940589688484,-20.447243463184265,-12.792114766505197,12.940829094330013,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-09-01,33.0,35.400001525878906,32.20000076293945,34.650001525878906,289961,0.0,0.0,51.94000053405762,67.7,78.5599999109904,-33.288407451673926,-23.279172032411203,-13.82382882293143,15.891715652843715,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-09-04,35.0,35.75,33.650001525878906,34.849998474121094,125514,0.0,0.0,49.06500053405762,66.56374988555908,78.15874989827473,-28.97177602203311,-26.288707264218885,-14.835191232980053,16.344100560395773,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-09-05,35.5,37.0,33.75,34.0,218058,0.0,0.0,46.17500038146973,65.40124988555908,77.75958321889242,-26.367082362506316,-29.397373196585658,-15.893003565290151,15.95141228549187,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-09-06,34.0,34.45000076293945,32.849998474121094,32.900001525878906,92258,0.0,0.0,42.93500022888183,64.21374988555908,77.33124987284343,-23.37253674043889,-33.13737275054013,-16.96274146461306,15.434590698268067,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-09-07,33.0,33.04999923706055,31.899999618530273,32.45000076293945,318396,0.0,0.0,39.94000015258789,63.09749994277954,76.9241665204366,-18.753128094725678,-36.70113682981451,-17.974411947620776,15.21737702648069,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-09-08,32.599998474121094,33.349998474121094,32.099998474121094,32.099998474121094,78742,0.0,0.0,36.820000076293944,62.00249986648559,76.50249986648559,-12.819124368258105,-40.615297519324095,-18.95362899945208,15.040086838166872,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-09-11,31.149999618530273,32.20000076293945,31.0,32.0,198482,0.0,0.0,33.69000015258789,60.87249994277954,76.07583322525025,-5.016325749283427,-44.65481098319165,-19.984445306639884,14.986365306394987,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-09-12,32.0,32.70000076293945,31.100000381469727,31.25,107070,0.0,0.0,33.21500015258789,59.75374994277954,75.66208321253458,-5.916002238629497,-44.41353022296555,-21.025502595624516,14.566127873000056,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-09-13,31.25,31.5,29.649999618530273,30.799999237060547,235003,0.0,0.0,32.829999923706055,58.62374992370606,75.2504165649414,-6.183370975824079,-43.99880600195045,-22.095115748477575,14.306900623866142,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-09-14,30.799999237060547,32.45000076293945,30.049999237060547,32.25,206305,0.0,0.0,32.725,57.5375,74.85249989827474,-1.4514896867838087,-43.12404953291332,-23.132159810034388,19.291123983261812,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-09-15,32.400001525878906,32.650001525878906,31.200000762939453,31.200000762939453,74879,0.0,0.0,32.37999992370605,56.380000019073485,74.44999990463256,-3.644222246902161,-42.56828678121351,-24.2713229129698,18.45407778467576,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-09-18,31.200000762939453,31.200000762939453,29.75,30.0,110332,0.0,0.0,31.895000076293947,55.207499980926514,74.02749993006388,-5.941370345700081,-42.227052325656366,-25.422984656941296,17.518528354426124,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-09-19,30.0,30.299999237060547,29.299999237060547,29.5,171048,0.0,0.0,31.445000076293944,54.19499998092651,73.60166660944621,-6.185403312370347,-41.97804209362348,-26.367156509508987,17.128876773753518,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-09-20,29.5,29.950000762939453,29.0,29.399999618530273,92184,0.0,0.0,31.094999885559083,53.17500004768372,73.18666663169861,-5.451038023048811,-41.52327248204005,-27.343322909787286,17.047209425510943,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-09-21,29.149999618530273,29.25,28.600000381469727,29.0,297502,0.0,0.0,30.749999809265137,52.075000047683716,72.73749995231628,-5.691056325593385,-40.95055250867371,-28.406942661183095,16.704136687892472,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-09-22,29.049999237060547,30.600000381469727,28.899999618530273,29.350000381469727,88927,0.0,0.0,30.475,50.93375005722046,72.28124996821086,-3.691549199443067,-40.167374352441165,-29.533938497714118,18.254349036590924,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-09-25,29.350000381469727,29.75,27.850000381469727,28.25,136799,0.0,0.0,30.1,49.76500005722046,71.80083328882853,-6.1461794019933595,-39.51572397188663,-30.69021935019327,17.172632109244944,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-09-26,28.149999618530273,28.399999618530273,27.200000762939453,27.5,83092,0.0,0.0,29.725,48.644999980926514,71.28333330154419,-7.485281749369223,-38.894028139263966,-31.758241754566306,16.456587357282515,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-09-27,27.5,28.0,27.350000381469727,27.850000381469727,44919,0.0,0.0,29.43000011444092,47.55374999046326,70.72624999682108,-5.368670495505389,-38.1121360137886,-32.763648585071806,18.171336891257923,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-09-28,27.899999618530273,28.0,26.75,26.950000762939453,71364,0.0,0.0,28.900000190734865,46.465000009536745,70.16166669527689,-6.747402819812325,-37.802646756045924,-33.774378235138684,17.19404343173825,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-09-29,27.049999237060547,28.049999237060547,27.049999237060547,27.200000762939453,77193,0.0,0.0,28.500000190734863,45.32499995231628,69.57083338101705,-4.561401470509567,-37.12079377668394,-34.85057207222766,18.50518758675112,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-10-02,27.200000762939453,27.200000762939453,24.850000381469727,24.950000762939453,245205,0.0,0.0,27.995000267028807,44.19124989509582,68.94208337465922,-10.876940435952099,-36.650354236449004,-35.900907352998516,16.043095824316666,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-10-03,24.950000762939453,24.950000762939453,22.25,22.5,451069,0.0,0.0,27.295000267028808,42.98624997138977,68.29875006675721,-17.567320828426453,-36.502950861739606,-37.06143973444061,13.877875413291562,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-10-04,22.5,22.899999618530273,21.049999237060547,21.149999618530273,326986,0.0,0.0,26.47000026702881,41.73999996185303,67.62500006357828,-20.098226652174084,-36.58361214369852,-38.277264439762256,12.848840241013178,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-10-05,21.299999237060547,22.25,20.799999237060547,20.950000762939453,147926,0.0,0.0,25.665000343322752,40.47624998092651,66.9795833905538,-18.371320932438632,-36.5924453094919,-39.569271810915865,12.698615347180322,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-10-06,20.950000762939453,21.799999237060547,20.899999618530273,21.25,195742,0.0,0.0,24.855000305175782,39.21750001907348,66.34833339055379,-14.504124968467934,-36.622680453655846,-40.8915069678947,14.316883743493634,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-10-09,21.25,21.299999237060547,20.100000381469727,20.350000381469727,90838,0.0,0.0,24.065000343322755,37.97874999046326,65.74375004768372,-15.437356778944814,-36.63561768261027,-42.232151401589654,13.507927554350417,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-10-10,20.399999618530273,21.0,20.100000381469727,20.549999237060547,126387,0.0,0.0,23.370000267028807,36.80000004768372,65.13750001589457,-12.066756515817477,-36.494564574056916,-43.504125828126746,14.661884014899726,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-10-11,20.350000381469727,21.0,20.0,20.149999618530273,98487,0.0,0.0,22.600000190734864,35.67375011444092,64.52291666666666,-10.840710404989276,-36.648095257060554,-44.71150413311923,14.252325827907285,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-10-12,20.149999618530273,20.5,19.34000015258789,19.520000457763672,126760,0.0,0.0,21.857000160217286,34.5667501449585,63.89725001653036,-10.69222530687112,-36.76871540263934,-45.90260122929234,13.607603720093607,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-10-13,20.299999237060547,20.299999237060547,18.3799991607666,18.559999465942383,191984,0.0,0.0,20.993000030517578,33.45325016975403,63.28941667874654,-11.58958015070898,-37.24675502681677,-47.14242613490845,12.667261470232233,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-10-16,18.600000381469727,19.1200008392334,18.260000228881836,18.84000015258789,89616,0.0,0.0,20.381999969482422,32.3342502117157,62.66308334668477,-7.565498082638299,-36.96467418905111,-48.399841685373495,14.522618958935553,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-10-17,18.84000015258789,19.899999618530273,18.479999542236328,19.559999465942383,116352,0.0,0.0,20.08799991607666,31.250750160217287,62.07358331680298,-2.6284371382922687,-35.71994331947585,-49.6553147242623,19.27195219027527,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-10-18,19.780000686645508,19.979999542236328,18.959999084472656,19.139999389648438,345499,0.0,0.0,19.886999893188477,30.09675006866455,61.473916657765706,-3.756225210198225,-33.92309851456696,-51.04143073196789,18.621959050691714,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-10-19,19.200000762939453,19.760000228881836,18.399999618530273,18.420000076293945,170253,0.0,0.0,19.633999824523926,28.997250032424926,60.850750017166135,-6.183150448609199,-32.29013164155548,-52.34693077037713,17.530411711156063,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-10-20,18.420000076293945,19.899999618530273,18.299999237060547,19.700000762939453,116984,0.0,0.0,19.478999900817872,27.907250070571898,60.27991671562195,1.1345595936488613,-30.200933981100448,-53.703900749850334,25.851538789572217,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-10-23,19.799999237060547,20.149999618530273,19.100000381469727,19.68000030517578,99725,0.0,0.0,19.411999893188476,26.81675009727478,59.716416692733766,1.380591456119597,-27.61240708596827,-55.09316937876847,25.807720805180224,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-10-24,19.68000030517578,19.959999084472656,19.100000381469727,19.260000228881836,29168,0.0,0.0,19.282999992370605,26.398250102996826,59.15275001525879,-0.11927481977840314,-26.953491549117764,-55.37274244022933,24.854982607322512,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-10-25,19.799999237060547,19.799999237060547,18.899999618530273,19.079999923706055,135408,0.0,0.0,19.176000022888182,26.009000062942505,58.575083335240684,-0.5006262988503506,-26.27167527978112,-55.59716080285174,24.438584705337576,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-10-26,19.059999465942383,19.799999237060547,18.799999237060547,19.200000762939453,73929,0.0,0.0,19.14400005340576,25.656500101089478,57.985916662216184,0.2925235550431831,-25.383431185172327,-55.75391133239196,25.336630288046138,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-10-27,19.200000762939453,20.450000762939453,19.200000762939453,19.84000015258789,135743,0.0,0.0,19.272000122070313,25.2862500667572,57.43124998410543,2.9472811691564034,-23.78466529757837,-55.97126986831146,30.10761595286222,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-10-30,19.860000610351562,20.200000762939453,19.3799991607666,19.520000457763672,86774,0.0,0.0,19.34000015258789,24.903000116348267,56.88475000063578,0.9307151176609239,-22.33867380544399,-56.222010088697,29.10614155808885,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-10-31,20.299999237060547,21.0,19.65999984741211,20.5,73169,0.0,0.0,19.43400020599365,24.565500116348268,56.35808335940043,5.48523094940373,-20.88905125501442,-56.411753821200904,36.11465221080547,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-11-01,20.600000381469727,23.0,20.600000381469727,22.700000762939453,260979,0.0,0.0,19.790000343322752,24.31050009727478,55.84641671180725,14.704398024927523,-18.594844761991457,-56.46900637738684,48.43799576897949,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-11-02,23.149999618530273,24.149999618530273,22.75,23.700000762939453,180653,0.0,0.0,20.318000411987306,24.09175009727478,55.33641670544942,16.645340497959726,-15.664074507041953,-56.46311862672114,52.886691920338855,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-11-03,23.75,24.0,23.100000381469727,23.899999618530273,47070,0.0,0.0,20.738000297546385,23.88675012588501,54.84308338165283,15.247368481125925,-13.181993413689469,-56.445282334588676,53.74622448704256,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-11-06,24.0,26.149999618530273,23.950000762939453,25.950000762939453,153607,0.0,0.0,21.365000343322755,23.735500144958497,54.37350002924601,21.460333938396854,-9.987149152781784,-56.347301291636875,61.49966592566451,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-11-07,25.950000762939453,26.75,24.600000381469727,25.0,96294,0.0,0.0,21.93900032043457,23.579250144958497,53.89183333714803,13.952320683975438,-6.956327340522448,-56.24708107915648,56.751970986406896,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-11-08,25.0,25.299999237060547,23.149999618530273,23.200000762939453,68009,0.0,0.0,22.35100040435791,23.389250183105467,53.40766665140788,3.7984892990114516,-4.439004117787003,-56.20619351194047,49.02881976668859,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-11-09,23.149999618530273,23.5,21.950000762939453,22.200000762939453,140738,0.0,0.0,22.65100040435791,23.138000202178954,52.97683331171672,-1.9910804528160537,-2.104761835792463,-56.324304878635324,45.337485444205136,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-11-10,22.200000762939453,22.200000762939453,19.81999969482422,20.399999618530273,199572,0.0,0.0,22.70700035095215,22.868000173568724,52.549333333969116,-10.159865665942702,-0.7040397996964378,-56.48279678785894,39.563402236917945,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-11-13,20.0,20.200000762939453,19.34000015258789,19.81999969482422,98271,0.0,0.0,22.737000274658204,22.61350016593933,52.096166690190636,-12.82931145092681,0.5461344232985618,-56.592775241182366,37.88893060207023,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-11-14,19.81999969482422,20.350000381469727,19.479999542236328,19.899999618530273,77038,0.0,0.0,22.67700023651123,22.37350015640259,51.5978333791097,-12.245890501468669,1.3565158691622465,-56.638682884190835,38.276971685993864,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-11-15,20.149999618530273,20.299999237060547,19.360000610351562,19.639999389648438,121997,0.0,0.0,22.37100009918213,22.129500150680542,51.11483338673909,-12.207772104178462,1.0913032235577218,-56.706304834749446,37.457901742866596,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-11-16,19.639999389648438,19.760000228881836,19.100000381469727,19.219999313354492,51048,0.0,0.0,21.922999954223634,21.885000133514403,50.62166670163472,-12.329519894691183,0.17363408945581374,-56.76752355368878,36.113546990963506,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-11-17,20.100000381469727,20.149999618530273,19.399999618530273,19.520000457763672,45587,0.0,0.0,21.48500003814697,21.639250135421754,50.1060000260671,-9.145913785871121,-0.7128255198745903,-56.81305607279733,37.82991390751982,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-11-20,19.579999923706055,19.579999923706055,19.079999923706055,19.18000030517578,68022,0.0,0.0,20.807999992370604,21.412500143051147,49.59416670799256,-7.823912378853038,-2.823118022846658,-56.82455908750993,36.6288515815927,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-11-21,19.100000381469727,19.899999618530273,18.68000030517578,18.799999237060547,117968,0.0,0.0,20.18799991607666,21.19500012397766,49.09833334287008,-6.8753748998719875,-4.751121500404206,-56.831528321000455,35.2806430452336,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-11-22,18.899999618530273,19.260000228881836,18.100000381469727,18.260000228881836,281441,0.0,0.0,19.6939998626709,20.955250120162965,48.60883334477742,-7.28140369548365,-6.0187793047552365,-56.89003689611404,33.399316523831544,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-11-23,18.239999771118164,18.84000015258789,14.199999809265137,14.539999961853027,877658,0.0,0.0,18.927999782562257,20.645000100135803,48.07249999841054,-23.182585963212812,-8.316785222792284,-57.05444879958728,23.931773900223263,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-11-24,15.0,16.0,14.520000457763672,15.699999809265137,356733,0.0,0.0,18.457999801635744,20.357500076293945,47.56583333015442,-14.94203067510161,-9.330714810460181,-57.201422426487206,30.543463506626026,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-11-27,15.720000267028809,15.979999542236328,14.579999923706055,14.619999885559082,146235,0.0,0.0,17.93799982070923,20.099250054359437,47.0493333419164,-18.497045201882276,-10.752889922783174,-57.28047853878314,28.09502569413226,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-11-28,14.65999984741211,15.579999923706055,14.5,15.140000343322754,192510,0.0,0.0,17.461999893188477,19.915250062942505,46.503000036875406,-13.297443386032096,-12.318450242906753,-57.174268225382576,30.964535612846205,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-11-29,15.34000015258789,15.5,14.65999984741211,15.220000267028809,162620,0.0,0.0,17.019999980926514,19.76700007915497,45.95483337243398,-10.575791515363555,-13.89689931313992,-56.986025998709835,31.41798577452913,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-11-30,12.260000228881836,13.199999809265137,8.010000228881836,8.010000228881836,7870532,0.0,0.0,15.899000072479248,19.443500065803526,45.363250041007994,-49.619471712897614,-18.229742491467405,-57.138211992688426,19.186427221042067,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-12-01,8.4399995803833,8.4399995803833,7.510000228881836,7.510000228881836,1342072,0.0,0.0,14.698000049591064,19.100000071525574,44.762500055631,-48.90461148766438,-23.047120447381804,-57.330354542780185,18.644339120271752,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-12-04,7.5,8.149999618530273,7.300000190734863,7.360000133514404,679607,0.0,0.0,13.516000032424927,18.77525006532669,44.1663333773613,-45.54601867521647,-28.011611108255313,-57.48967906185648,18.475690552407286,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-12-05,7.28000020980835,7.599999904632568,6.840000152587891,7.400000095367432,617261,0.0,0.0,12.376000118255615,18.44650008678436,43.5871666987737,-40.20685177231192,-32.90868153833604,-57.67905674102156,18.686917253155357,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-12-06,7.550000190734863,8.630000114440918,7.329999923706055,8.25,649767,0.0,0.0,11.375000095367431,18.149000096321107,43.025083390871686,-27.472528080594174,-37.32437029589745,-57.8176294710642,23.238368219301364,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-12-07,8.449999809265137,8.760000228881836,7.849999904632568,8.260000228881836,699278,0.0,0.0,10.747000122070313,17.86750009059906,42.45058341821035,-23.141340513071277,-39.85168564389811,-57.909883323454395,23.292768544611747,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-12-08,8.25,8.640000343322754,8.0,8.130000114440918,485837,0.0,0.0,9.990000152587891,17.606750106811525,41.87000006039937,-18.618618716088243,-43.260396768378854,-57.94900864243374,23.06394048127335,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-12-11,8.130000114440918,8.210000038146973,7.900000095367432,8.180000305175781,209177,0.0,0.0,9.34600019454956,17.340250110626222,41.303166755040486,-12.475924086260687,-46.102275717336575,-58.01714136480811,23.375734019796525,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-12-12,8.239999771118164,8.59000015258789,8.039999961853027,8.1899995803833,131641,0.0,0.0,8.651000118255615,17.056000113487244,40.75891675154368,-5.328869859792236,-49.278845797997334,-58.153941584227034,23.4425539707493,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-12-13,8.100000381469727,9.020000457763672,8.0600004196167,8.770000457763672,365541,0.0,0.0,8.006000137329101,16.796750140190124,40.196166729927064,9.542846706588373,-52.33601696453836,-58.21305485907312,27.39746244871482,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-12-14,8.770000457763672,9.15999984741211,8.770000457763672,8.90999984741211,307592,0.0,0.0,8.09600009918213,16.55900013446808,39.62541671593984,10.054344593106066,-51.10815850330207,-58.21116468459244,28.35949510397215,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-12-15,8.920000076293945,8.930000305175781,8.569999694824219,8.630000114440918,157368,0.0,0.0,8.208000087738037,16.282250118255615,39.05400007565816,5.141325806432532,-49.5892764935772,-58.308367678822925,27.572573488182584,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-12-18,8.699999809265137,8.899999618530273,8.170000076293945,8.199999809265137,155908,0.0,0.0,8.29200005531311,15.99525010585785,38.4423334201177,-1.1095060954446612,-48.15960988145863,-58.391573344277816,26.36275663285953,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-12-19,8.25,8.5,8.25,8.390000343322754,71319,0.0,0.0,8.391000080108643,15.723500108718872,37.80058341026306,-0.01191439371165443,-46.63401900283174,-58.404080862810545,27.868795749823008,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-12-20,8.390000343322754,8.75,8.3100004196167,8.640000343322754,167511,0.0,0.0,8.430000114440919,15.46250011920929,37.1784167210261,2.4911058841161418,-45.481002105421446,-58.41000913181832,29.90033193287013,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-12-21,8.640000343322754,8.960000038146973,8.4399995803833,8.760000228881836,128509,0.0,0.0,8.480000114440918,15.20150010585785,36.5747500816981,3.3018880974316898,-44.21603094833268,-58.437172989830934,30.906256943043743,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-12-22,9.180000305175781,10.899999618530273,8.949999809265137,10.5,755388,0.0,0.0,8.717000102996826,14.968000102043153,35.98475005626678,20.454283307742475,-41.76242621880432,-58.40460173090334,43.55454303904421,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-12-27,10.600000381469727,10.619999885559082,9.649999618530273,9.800000190734863,412202,0.0,0.0,8.879000091552735,14.725000095367431,35.39725003242493,10.372790738659251,-39.70118822378738,-58.40072298870987,40.35407311518862,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-12-28,10.039999961853027,10.100000381469727,9.5,9.510000228881836,160698,0.0,0.0,9.011000156402588,14.450250101089477,34.80566670099894,5.537676881790901,-37.64121663386848,-58.48305327627944,39.07309187472571,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2023-12-29,9.510000228881836,10.140000343322754,9.40999984741211,10.0,163619,0.0,0.0,9.134000110626221,14.132750082015992,34.219000021616615,9.48105845068143,-35.36997358886795,-58.69911431342781,42.40014259173088,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-01-02,10.0,10.84000015258789,9.819999694824219,10.239999771118164,245565,0.0,0.0,9.267000102996827,13.796250057220458,33.66183336575826,10.499618617751846,-32.82957278563667,-59.015155510649095,44.012787540346295,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-01-03,10.260000228881836,10.260000228881836,9.600000381469727,9.75,117928,0.0,0.0,9.379000091552735,13.442500066757201,33.1105833530426,3.955644576455533,-30.228751757668576,-59.40119833158438,41.4605441767067,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-01-04,9.75,9.760000228881836,9.5,9.600000381469727,76017,0.0,0.0,9.519000148773193,13.033750057220459,32.5472500483195,0.850932150757166,-26.966528382214594,-59.9543739090995,40.68280661372847,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-01-05,9.510000228881836,9.510000228881836,9.109999656677246,9.25,106791,0.0,0.0,9.605000114440918,12.640000057220458,31.9910000483195,-3.6959928184402866,-24.011075387977005,-60.48888738042297,38.85146838640171,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-01-08,9.300000190734863,9.390000343322754,9.0,9.319999694824219,196185,0.0,0.0,9.673000049591064,12.293000030517579,31.4353333791097,-3.6493368443823018,-21.31294211683333,-60.894322696488814,39.438640715867244,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-01-09,9.319999694824219,9.319999694824219,8.90999984741211,9.180000305175781,104020,0.0,0.0,9.71500005722046,11.967500019073487,30.881000073750815,-5.506945433799059,-18.82180871746858,-61.246397492010004,38.63949555195283,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-01-10,9.180000305175781,9.180000305175781,8.829999923706055,8.869999885559082,87919,0.0,0.0,9.552000045776367,11.679250025749207,30.309083406130473,-7.139867639749927,-18.213926196313103,-61.46617213971274,36.85850241563296,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-01-11,8.869999885559082,8.90999984741211,8.600000381469727,8.609999656677246,124916,0.0,0.0,9.432999992370606,11.399000024795532,29.74000005722046,-8.724693484140793,-17.247127187897267,-61.67114995674652,35.38534106700203,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-01-12,8.609999656677246,8.640000343322754,8.199999809265137,8.380000114440918,173339,0.0,0.0,9.319999980926514,11.111000037193298,29.226500058174132,-10.085835497954044,-16.119161644060263,-61.983131695285735,34.08743035002425,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-01-15,8.239999771118164,8.25,7.880000114440918,7.880000114440918,149514,0.0,0.0,9.107999992370605,10.81700005531311,28.707166751225788,-13.482651284127487,-15.799205456258425,-62.319513628591615,31.391771248655587,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-01-16,7.929999828338623,8.180000305175781,7.869999885559082,7.900000095367432,123811,0.0,0.0,8.874000024795532,10.534000074863433,28.16466675202052,-10.975883780781736,-15.758496661007692,-62.59852755364936,31.624695249667496,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-01-17,7.940000057220459,7.940000057220459,7.539999961853027,7.679999828338623,124379,0.0,0.0,8.667000007629394,10.238000059127808,27.603666750590005,-11.388025596191687,-15.344794319450807,-62.910724319228414,30.401999259069527,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-01-18,7.679999828338623,8.229999542236328,7.670000076293945,8.15999984741211,122155,0.0,0.0,8.522999954223632,9.962500047683715,27.04666674931844,-4.259064986051484,-14.449185310616558,-63.165516327682916,36.1980089242543,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-01-19,8.25,8.289999961853027,7.619999885559082,7.71999979019165,179501,0.0,0.0,8.369999933242799,9.685500061511993,26.508500055472055,-7.76583211750777,-13.58216013540382,-63.462662763853174,33.448207414786765,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-01-22,4.25,4.25,1.7519999742507935,2.0199999809265137,6777545,0.0,0.0,7.639999961853027,9.279500055313111,25.92950005531311,-73.56020954172129,-17.667978702380253,-64.21257627213029,16.23857930763141,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-01-23,2.0199999809265137,2.0999999046325684,1.8079999685287476,1.8580000400543213,1447385,0.0,0.0,6.907799935340881,8.962450057268143,25.35748338898023,-73.10286838869438,-22.92509424095516,-64.65560118965506,15.986820065215056,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-01-24,1.8600000143051147,1.9759999513626099,1.6200000047683716,1.7139999866485596,965411,0.0,0.0,6.192199945449829,8.612800061702728,24.765100030104318,-72.32001547514552,-28.104682552846267,-65.22202595090245,15.753025798371183,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-01-25,1.718000054359436,1.7200000286102295,1.5740000009536743,1.6200000047683716,612290,0.0,0.0,5.493199980258941,8.28780006468296,24.192766671379406,-70.50899274393416,-33.71944379224022,-65.74265284636661,15.592722112074114,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-01-26,1.6920000314712524,1.7580000162124634,1.5800000429153442,1.590000033378601,734568,0.0,0.0,4.81419997215271,7.9490500569343565,23.61685003042221,-66.97270486112318,-39.4367888279551,-66.3416160635532,15.538376695142091,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-01-29,1.6319999694824219,1.7059999704360962,1.5920000076293945,1.6699999570846558,521423,0.0,0.0,4.193199956417084,7.610300049185753,23.03910003006458,-60.17361503285902,-44.90099037730154,-66.96789354074252,16.37538264473268,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-01-30,1.6699999570846558,1.7480000257492065,1.600000023841858,1.6139999628067017,241157,0.0,0.0,3.564599943161011,7.450400042533874,22.456716696421307,-54.72142769055197,-52.15558999770577,-66.82328880374054,16.253956749528115,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-01-31,1.649999976158142,1.6679999828338623,1.5800000429153442,1.600000023841858,290791,0.0,0.0,2.9565999627113344,7.302650037407875,21.873383376002312,-45.88378394030059,-59.51332807178037,-66.61398965182612,16.22157236494678,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-02-01,1.600000023841858,1.6339999437332153,1.5800000429153442,1.6100000143051147,100766,0.0,0.0,2.3015999794006348,7.158900034427643,21.30430003007253,-30.048660552891615,-67.84980977060607,-66.39692445035816,16.34977642575079,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-02-02,1.600000023841858,1.600000023841858,1.4279999732971191,1.5240000486373901,361476,0.0,0.0,1.6820000052452087,7.012000033259392,20.75283338924249,-9.393576463442677,-76.0125499534066,-66.2118424904131,16.121293974621537,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-02-05,1.5299999713897705,1.5299999713897705,1.3760000467300415,1.4220000505447388,212323,0.0,0.0,1.6222000122070312,6.841300034523011,20.221350081761678,-12.341262492651381,-76.2881323137272,-66.16793633035704,15.83858219606357,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-02-06,1.4220000505447388,1.4220000505447388,1.190000057220459,1.246000051498413,421744,0.0,0.0,1.5610000133514403,6.665950030088425,19.700066755215328,-20.17936958096033,-76.58248252228897,-66.16280486296472,15.338742273212617,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-02-07,1.246000051498413,1.4500000476837158,1.246000051498413,1.2979999780654907,382405,0.0,0.0,1.5194000124931335,6.495150026679039,19.18505010108153,-14.57154354397791,-76.6071606313611,-66.14473252632848,16.180398955270633,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-02-08,1.2979999780654907,1.2999999523162842,1.25,1.2619999647140503,165379,0.0,0.0,1.4836000084877015,6.3222000181674955,18.665566780169804,-14.936643468985809,-76.53348511239089,-66.12907557200906,16.061352358548888,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-02-09,1.2619999647140503,1.2619999647140503,1.2000000476837158,1.2319999933242798,167453,0.0,0.0,1.4478000044822692,6.14825002849102,18.151666767398517,-14.905374394936482,-76.45183592448002,-66.12845471836422,15.95599749709632,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-02-12,1.315999984741211,1.3980000019073486,1.2380000352859497,1.350000023841858,283815,0.0,0.0,1.4158000111579896,5.962750017642975,17.618750075499218,-4.647548156346852,-76.25592206668354,-66.15679323396031,18.228072521079937,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-02-13,1.3660000562667847,1.3700000047683716,1.2940000295639038,1.3600000143051147,122157,0.0,0.0,1.3904000163078307,5.7740000218153,17.110083396236103,-2.1864212921575152,-75.91963957300611,-66.25381719012853,18.429330042346876,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-02-14,0.15440499782562256,0.3435010015964508,0.15440499782562256,0.2834160029888153,73613473,0.0,0.0,1.2587416142225265,5.565335419028997,16.584945202618837,-77.48417945458411,-77.38246629450875,-66.44345006246867,14.337963580077755,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-02-15,0.29475298523902893,0.3911150097846985,0.25110700726509094,0.2698119878768921,47027532,0.0,0.0,1.1247228115797043,5.367080723494292,16.059693642208973,-76.0108014971321,-79.04404890620982,-66.58042897289003,14.294777865753701,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-02-16,0.2720800042152405,0.3355650007724762,0.23693600296974182,0.25564199686050415,24145904,0.0,0.0,0.9978870064020157,5.163721764832735,15.76182399218281,-74.38166894443813,-80.67504308233502,-67.23905959491921,14.246643821387295,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-02-19,0.25847598910331726,0.30495598912239075,0.22038400173187256,0.24147099256515503,8876596,0.0,0.0,0.8798341006040573,4.953758531063795,15.47508623773853,-72.55494048260108,-82.23905959309815,-67.98881469892399,14.195164701082732,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-02-20,0.24203799664974213,0.26187700033187866,0.22038400173187256,0.24317100644111633,4263983,0.0,0.0,0.7795511960983277,4.740837800502777,15.199612669150035,-68.80628140163302,-83.55667861035757,-68.80948282238111,14.235201941828862,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-02-21,0.24317100644111633,0.278315007686615,0.22673299908638,0.25620800256729126,4591786,0.0,0.0,0.6753719985485077,4.48474300056696,14.912997723122437,-62.06416565715976,-84.94067556461702,-69.92728702953252,14.56443302963747,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-02-22,0.26074299216270447,0.2766140103340149,0.23806999623775482,0.2726469933986664,2845419,0.0,0.0,0.5764367014169693,4.246559170633555,14.62485312744975,-52.701312611001605,-86.42579372487657,-70.96340637662144,15.007485077103212,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-02-23,0.515999972820282,1.4299999475479126,0.515999972820282,0.7360000014305115,8451321,0.0,0.0,0.5268367022275925,4.027209164947271,14.347653127461673,39.70173268463002,-86.91806954520351,-71.93123412470072,26.566752097540814,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-02-26,0.800000011920929,0.8289999961853027,0.6809999942779541,0.699999988079071,1733852,0.0,0.0,0.46183669865131377,3.794709164649248,14.07931978131334,51.568723343826406,-87.82945731510357,-73.04763849681328,26.267836022598644,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-02-27,0.7400000095367432,0.7400000095367432,0.628000020980835,0.6610000133514404,1769917,0.0,0.0,0.3919366985559464,3.55523417070508,13.814411441733439,68.64968648938269,-88.97578387985013,-74.26430951691006,25.927492358782317,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-02-28,0.6809999942779541,0.6880000233650208,0.5139999985694885,0.5600000023841858,2135861,0.0,0.0,0.4195950984954834,3.3254841707646845,13.551578121135632,33.46199810058405,-87.38243585146884,-75.46053942176584,25.023262018040242,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-02-29,0.5600000023841858,0.8690000176429749,0.45350000262260437,0.7689999938011169,3481949,0.0,0.0,0.46951389908790586,3.1047091610729693,13.291319787750641,63.78641724877651,-84.87736291132518,-76.64107695358976,30.430170631781436,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-03-01,0.7749999761581421,0.8489999771118164,0.6499999761581421,0.6800000071525574,1815155,0.0,0.0,0.5119497001171112,2.8904591612517834,13.036569787810246,32.82555043923335,-82.28829152890023,-77.8280697430509,29.45602261900352,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-03-04,0.6949999928474426,0.7080000042915344,0.5649999976158142,0.5899999737739563,974829,0.0,0.0,0.5468025982379914,2.672209168225527,12.784819793949525,7.899994563881648,-79.53743274516589,-79.0985777563313,28.463707868275293,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-03-05,0.7070000171661377,1.5499999523162842,0.6399999856948853,0.9380000233650208,21872809,0.0,0.0,0.6162854999303817,2.466159161180258,12.5238864608109,52.20218932150461,-75.01031119031916,-80.30835580554619,37.264291390993435,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-03-06,0.9649999737739563,0.9769999980926514,0.6830000281333923,0.699999988079071,5909101,0.0,0.0,0.6606646984815597,2.2619091637432573,12.269719787687063,5.953896081918357,-70.79172280339415,-81.56511148679097,34.168358376206925,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-03-07,0.699999988079071,0.8519999980926514,0.699999988079071,0.800000011920929,4036380,0.0,0.0,0.713400000333786,2.0666591726243495,12.026386454453071,12.139054043541416,-65.48051997234387,-82.81562645229052,36.553499744366654,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-03-08,0.800000011920929,0.9300000071525574,0.7509999871253967,0.800000011920929,3953960,0.0,0.0,0.7198000013828277,1.87715917006135,11.787219787885745,11.141985327039004,-61.65482326363924,-84.07462316100535,36.553499744366654,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-03-11,0.8999999761581421,1.7000000476837158,0.8009999990463257,1.1180000305175781,10238040,0.0,0.0,0.7616000056266785,1.7081091679632663,11.55153645798564,46.796221409903715,-55.412685564190056,-85.21314308121806,44.03201706417636,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-03-12,1.2020000219345093,1.6180000305175781,1.2000000476837158,1.4179999828338623,10519477,0.0,0.0,0.8373000025749207,1.5460591651499271,11.321686457842588,69.35387298138474,-45.84295210372984,-86.34426795948792,50.017565651683725,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-03-13,1.4620000123977661,1.99399995803833,1.25,1.5679999589920044,8151215,0.0,0.0,0.9380999982357026,1.3932591684162616,11.090169787655274,67.14635560611484,-32.66866499058788,-87.43698973872222,52.73914242996374,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-03-14,1.5800000429153442,1.7519999742507935,1.3940000534057617,1.440000057220459,3700161,0.0,0.0,1.0052000045776368,1.2252591736614704,10.866753121465445,43.25507865725843,-17.96021395426289,-88.72469853721829,50.22590186991844,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-03-15,1.440000057220459,1.496000051498413,1.065999984741211,1.1480000019073486,2586767,0.0,0.0,1.052000004053116,1.0609591789543629,10.64715312148134,9.125475046042459,-0.844441056636766,-90.03527828660783,44.962034570782926,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-03-18,1.1480000019073486,1.284000039100647,1.0,1.0119999647140503,1716107,0.0,0.0,1.0942000031471253,1.0357591785490512,10.423503118008375,-7.512341271856352,5.642317809815718,-90.06323337919282,42.71653005802409,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-03-19,1.0920000076293945,1.1699999570846558,0.8510000109672546,1.1100000143051147,1397293,0.0,0.0,1.1114000022411346,1.017059177905321,10.208169778436423,-0.12596616278538217,9.275844157870207,-90.03681169122265,44.85378172343855,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-03-20,1.1399999856948853,1.2319999933242798,0.41999998688697815,0.4975000023841858,19867973,0.0,0.0,1.0911500036716462,0.9866466782987118,9.985648938765129,-54.405901964887335,10.591767820384383,-90.11935344063153,35.85074500865106,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-03-21,0.4975000023841858,0.6830000281333923,0.42500001192092896,0.6309999823570251,20805953,0.0,0.0,1.0742500007152558,0.9619216777384281,9.782990598926942,-41.261346805967555,11.677491585481532,-90.1674067044086,38.7370844232626,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-03-22,0.6140000224113464,0.6140000224113464,0.4000000059604645,0.4959999918937683,14555879,0.0,0.0,1.0438499987125396,0.9345716767013073,9.599623932192722,-52.48359510413151,11.692877575419837,-90.26449699172919,36.92764274634992,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-03-25,0.24050000309944153,0.2800000011920929,0.23800000548362732,0.265500009059906,89924221,0.0,0.0,0.9585999965667724,0.8994591780006885,9.425586435447137,-72.30335802098949,6.575153160095789,-90.45726030777183,34.006818001803055,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-03-26,0.2705000042915344,0.27149999141693115,0.25,0.25999999046325684,30914024,0.0,0.0,0.8427999973297119,0.8656091786921024,9.253169762343168,-69.15045191183809,-2.63504384240174,-90.64526858444987,33.9378391367642,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-03-27,0.2605000138282776,0.2930000126361847,0.2549999952316284,0.28999999165534973,42937055,0.0,0.0,0.7150000005960464,0.8328591778874397,9.078503095606964,-59.44056064145501,-14.151153090531455,-90.82602969766619,34.715697655042675,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-03-28,0.29499998688697815,0.31450000405311584,0.2854999899864197,0.30149999260902405,42905004,0.0,0.0,0.601149994134903,0.8001466773450374,8.911432259033123,-49.846128994328,-24.870025564615762,-91.02112147535023,35.03149754971669,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-04-02,0.3100000023841858,0.32499998807907104,0.28999999165534973,0.29499998688697815,36356451,0.0,0.0,0.5158499926328659,0.7694216758012772,8.74264059861501,-42.81283491324353,-32.95613980517786,-91.19920729758503,34.928651980931036,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-04-03,0.30000001192092896,0.3050000071525574,0.2815000116825104,0.28600001335144043,16319873,0.0,0.0,0.44324999749660493,0.7410216748714447,8.577107268571854,-35.47658996802791,-40.18393624268795,-91.36047094121477,34.776413706884966,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-04-04,0.29899999499320984,0.35199999809265137,0.2750000059604645,0.3375000059604645,64465189,0.0,0.0,0.3659999966621399,0.718309173732996,8.41725309814016,-7.786882776390894,-49.04701066811289,-91.4662281701888,36.48244279498852,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-04-05,0.33799999952316284,0.3555000126361847,0.3160000145435333,0.33000001311302185,60142853,0.0,0.0,0.3492499977350235,0.6941091746091843,8.265336436033248,-5.511806656218409,-49.68370819595239,-91.60216671177265,36.33339481276975,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-04-08,0.3400000035762787,0.3935000002384186,0.32350000739097595,0.38999998569488525,84136471,0.0,0.0,0.3251499980688095,0.6723091751337051,8.111586434642474,19.94463724780707,-51.63683464469372,-91.7117424495109,38.49813299173919,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-04-09,0.3944999873638153,0.4269999861717224,0.3765000104904175,0.39500001072883606,80841607,0.0,0.0,0.3150499999523163,0.651384175568819,7.951878105849028,25.37692772214582,-51.633765177485316,-91.80842353343304,38.685229035465184,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-04-10,0.39649999141693115,0.39750000834465027,0.3709999918937683,0.3815000057220459,34945344,0.0,0.0,0.32664999961853025,0.6271716751158237,7.795557277649641,16.791674932671302,-47.91697192667291,-91.95475508962055,38.346038873949205,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-04-11,0.38999998569488525,0.39399999380111694,0.36399999260902405,0.38999998569488525,29028820,0.0,0.0,0.33964999914169314,0.602921674400568,7.645307276894649,14.82407969392852,-43.66598290244296,-92.1138333285479,38.71041791667979,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-04-12,0.39500001072883606,0.3955000042915344,0.3675000071525574,0.3700000047683716,20630369,0.0,0.0,0.3476500004529953,0.6050862744450569,7.4842239372432235,6.428880853229894,-42.54538317336057,-91.91517678360735,38.13925374124486,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-04-15,0.3700000047683716,0.3725000023841858,0.34299999475479126,0.3580000102519989,22358570,0.0,0.0,0.3533000022172928,0.6072909750044346,7.323207268118859,1.3303164464220476,-41.82360404504399,-91.70730865903197,37.77907295149234,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-04-16,0.36000001430511475,0.36149999499320984,0.33000001311302185,0.34049999713897705,25396490,0.0,0.0,0.35785000324249266,0.6094124250113964,7.165544766187668,-4.8484018293437305,-41.27950324678715,-91.49523944240703,37.22693494217254,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-04-17,0.3384999930858612,0.3504999876022339,0.32199999690055847,0.34150001406669617,19843079,0.0,0.0,0.3634000033140182,0.6119131505489349,7.009390600274006,-6.026414157293781,-40.61248675763555,-91.27009485639145,37.283341931156464,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-04-18,0.35899999737739563,0.36800000071525574,0.34299999475479126,0.36399999260902405,24708155,0.0,0.0,0.3660500019788742,0.6149338752031326,6.852423927187919,-0.560035339097876,-40.47327416172088,-91.0260386435915,38.619775847497316,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-04-19,0.367000013589859,0.3725000023841858,0.35199999809265137,0.35199999809265137,20968653,0.0,0.0,0.36825000047683715,0.6173286750912667,6.6900239259004595,-4.412763710290315,-40.3478219406551,-90.77239959185682,38.15282102746724,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-04-22,0.23749999701976776,0.2680000066757202,0.20999999344348907,0.23499999940395355,198129347,0.0,0.0,0.35275000184774397,0.6163875002413988,6.529315588747462,-33.380581666053224,-42.7713894734084,-90.55969202493944,33.85474447150311,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-04-23,0.2395000010728836,0.23999999463558197,0.20999999344348907,0.21549999713897705,64018495,0.0,0.0,0.3348000004887581,0.6033750001341105,6.36027808872362,-35.6332148075331,-44.51211926010474,-90.51338649478461,33.183768928756095,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-04-24,0.2160000056028366,0.2175000011920929,0.18619999289512634,0.20800000429153442,49579617,0.0,0.0,0.3174500003457069,0.5910750005394221,6.17284474906822,-34.47786925026937,-46.292771635410354,-90.42459312412412,32.913576547850454,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-04-25,0.21150000393390656,0.23649999499320984,0.20800000429153442,0.21649999916553497,37415150,0.0,0.0,0.3001000016927719,0.5799625001847744,5.977148909370104,-27.857381558038984,-48.25527485015653,-90.29700432466065,33.57370720324079,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-04-26,0.22750000655651093,0.22750000655651093,0.21299999952316284,0.2134999930858612,11591005,0.0,0.0,0.28445000052452085,0.5712999999523163,5.779761412491401,-24.942874778635634,-50.21004716466611,-90.11550894267702,33.44860601364309,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-04-29,0.21649999916553497,0.2175000011920929,0.20499999821186066,0.20800000429153442,12043926,0.0,0.0,0.2694499999284744,0.5572750002145768,5.565244739502669,-22.805713732882502,-51.64864746763741,-89.98651404745989,33.20432978148219,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-04-30,0.20800000429153442,0.21649999916553497,0.20499999821186066,0.21649999916553497,5244928,0.0,0.0,0.2570500001311302,0.5456875000149012,5.358715572829047,-15.775141390744707,-52.89428470981819,-89.8168228449786,34.006462334924606,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-05-02,0.21799999475479126,0.2199999988079071,0.20550000667572021,0.20550000667572021,8340380,0.0,0.0,0.24344999939203263,0.5360750008374453,5.167094733193517,-15.588413559698042,-54.58657855491862,-89.62521438994163,33.446692595898185,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-05-03,0.20499999821186066,0.20999999344348907,0.19900000095367432,0.20200000703334808,12159091,0.0,0.0,0.22725000083446503,0.5176750004291535,4.983778060227633,-11.111108342529652,-56.10180119842095,-89.61279988448145,33.25909868719549,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-05-06,0.2070000022649765,0.20800000429153442,0.1979999989271164,0.20350000262260437,8327761,0.0,0.0,0.21240000128746034,0.5052625007927418,4.815473896761735,-4.1902065023110735,-57.962445074746086,-89.5075227978597,33.43142099635753,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-05-07,0.20350000262260437,0.20350000262260437,0.19480000436306,0.20000000298023224,7806572,0.0,0.0,0.2089000016450882,0.4902625005692244,4.651973899329702,-4.260411007548324,-57.390173345392995,-89.46119408279857,33.21591549234141,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-05-08,0.1979999989271164,0.1979999989271164,0.18940000236034393,0.19040000438690186,10856416,0.0,0.0,0.20639000236988067,0.4750225003808737,4.487727235878507,-7.747467318849307,-56.55153130548618,-89.41507637578414,32.59526669028867,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-05-10,0.24500000476837158,0.25850000977516174,0.2199999988079071,0.22949999570846558,108790003,0.0,0.0,0.20854000151157379,0.4528099995106459,4.325973074262341,10.050826721476037,-53.94536301385923,-89.53275964187876,37.70113928892333,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-05-13,0.23350000381469727,0.23499999940395355,0.2084999978542328,0.21299999952316284,23614750,0.0,0.0,0.20819000154733658,0.4226849999278784,4.167581413313746,2.3103885585651454,-50.74582689642181,-89.85778661509599,36.446476565309545,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-05-14,0.21299999952316284,0.22599999606609344,0.20149999856948853,0.2150000035762787,18640069,0.0,0.0,0.20834000259637833,0.38886000104248525,4.006706409528851,3.196698136172591,-46.42287660395908,-90.29477178268694,36.72136806931851,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-05-15,0.21899999678134918,0.22599999606609344,0.20800000429153442,0.2214999943971634,13076139,0.0,0.0,0.20969000160694123,0.35839749947190286,3.8487189069390295,5.632120129580474,-41.492336884069076,-90.68787541678526,37.665037609561786,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-05-16,0.19599999487400055,0.21199999749660492,0.1817999929189682,0.20800000429153442,33897156,0.0,0.0,0.20884000211954118,0.3348974995315075,3.693785579999288,-0.402220752481096,-37.64062066402699,-90.93348836096837,36.44925235824429,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-05-17,0.20749999582767487,0.20749999582767487,0.1979999989271164,0.20200000703334808,10301294,0.0,0.0,0.20849000215530394,0.3146475005894899,3.5433022448172173,-3.1128567580528257,-33.73854813252946,-91.11993618242067,35.89468928392753,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-05-20,0.20200000703334808,0.2290000021457672,0.20000000298023224,0.2290000021457672,15585008,0.0,0.0,0.21119000166654586,0.29262250028550624,3.424043911819657,8.433164609441164,-27.828515763315615,-91.45389171922167,40.29676496925134,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-05-21,0.23000000417232513,0.24150000512599945,0.20800000429153442,0.21199999749660492,17222242,0.0,0.0,0.21204000115394592,0.28548500016331674,3.2949772467215857,-0.018866089946846534,-25.72639507061853,-91.33575200109904,38.50393679164775,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-05-22,0.21199999749660492,0.2434999942779541,0.2084999978542328,0.22499999403953552,31211658,0.0,0.0,0.21454000025987624,0.2753350004553795,3.1750189142922562,4.8755447781247785,-22.080374850619705,-91.32808314256124,40.677473629260085,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-05-23,0.22599999606609344,0.273499995470047,0.22300000488758087,0.25,54266292,0.0,0.0,0.22049999982118607,0.2691850006580353,3.0509355780978997,13.378684899200403,-18.086074899357868,-91.17696871115652,44.72361352136205,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-05-24,0.25999999046325684,0.265500009059906,0.2345000058412552,0.24500000476837158,32256087,0.0,0.0,0.22205000072717668,0.26867250055074693,2.9261439092457295,10.335511806366798,-17.352910970791438,-90.81820618248393,44.0761150824836,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-05-27,0.2475000023841858,0.27649998664855957,0.23399999737739563,0.2759999930858612,33070749,0.0,0.0,0.2283500000834465,0.26907250061631205,2.861693907280763,20.867086921393412,-15.134397026671415,-90.59743951190119,49.00559386511109,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-05-28,0.2775000035762787,0.3095000088214874,0.2694999873638153,0.2919999957084656,51772616,0.0,0.0,0.2360499992966652,0.26912250071763993,2.8015439053376516,23.702603930738842,-12.289013862751668,-90.39377893721768,51.387344139725435,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-05-29,0.29350000619888306,0.29499998688697815,0.26499998569488525,0.27000001072883606,19791051,0.0,0.0,0.24090000092983246,0.26833500117063525,2.742460570981105,12.079705141835856,-10.224160143520287,-90.21553841065291,48.0632462863508,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-05-30,0.27250000834465027,0.2815000116825104,0.2549999952316284,0.25699999928474426,18822229,0.0,0.0,0.24580000042915345,0.26738500148057937,2.6829355701804163,4.556549567142482,-8.072629703201086,-90.0338642324311,46.162967249109585,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-05-31,0.2685000002384186,0.3019999861717224,0.2554999887943268,0.2980000078678131,50774386,0.0,0.0,0.2554000005125999,0.2676850013434887,2.6166689035793147,16.67972093567461,-4.589349709259539,-89.77000869398016,52.5366127164465,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-06-03,0.29750001430511475,0.3580000102519989,0.2815000116825104,0.3555000126361847,55502902,0.0,0.0,0.2680500015616417,0.2681350015103817,2.550798068443934,32.62451429399923,-0.03170043010468905,-89.48819176133561,59.735954773321325,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-06-04,0.35350000858306885,0.35499998927116394,0.3199999928474426,0.3310000002384186,33900717,0.0,0.0,0.2799500018358231,0.26816000118851663,2.48580640082558,18.235398488239273,4.396629100183393,-89.21235374164874,55.84880670164124,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-06-05,0.33149999380111694,0.3504999876022339,0.30399999022483826,0.3230000138282776,25084526,0.0,0.0,0.2897500038146973,0.2664850018918514,2.420331398397684,11.475413140924253,8.730323191804837,-88.9897308249494,54.59943672395578,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-06-07,0.3215000033378601,0.32850000262260437,0.296999990940094,0.32199999690055847,26667046,0.0,0.0,0.2969500035047531,0.2646600015461445,2.3547647352019947,8.435761272993021,12.200559876811875,-88.76066056240468,54.43550529980929,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-06-10,0.3269999921321869,0.3269999921321869,0.29750001430511475,0.3084999918937683,13801648,0.0,0.0,0.3033000022172928,0.26283500120043757,2.2842522313197455,1.7144707017674472,15.395590705971726,-88.49360864808776,52.15876944192919,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-06-11,0.3100000023841858,0.3334999978542328,0.2930000126361847,0.3059999942779541,27325851,0.0,0.0,0.30630000233650206,0.26073500141501427,2.2125522325436275,-0.09794582313400468,17.47559808779243,-88.21564537189414,51.727309355594706,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-06-12,0.30550000071525574,0.31150001287460327,0.2849999964237213,0.30550000071525574,17975996,0.0,0.0,0.3076500028371811,0.25912250131368636,2.14318139826258,-0.6988467746132926,18.727629317204183,-87.9094461381687,51.63531321529996,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-06-13,0.3059999942779541,0.3059999942779541,0.2904999852180481,0.2985000014305115,9195501,0.0,0.0,0.3105000019073486,0.2576350010931492,2.0773355665306252,-3.8647344293472394,20.51933960443745,-87.59781494891422,50.28690046032134,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-06-14,0.304500013589859,0.31299999356269836,0.28200000524520874,0.28850001096725464,13169811,0.0,0.0,0.31365000307559965,0.2563350014388561,2.009823063760996,-8.018489354926949,22.359413000574925,-87.24589213544128,48.34462636507659,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-06-17,0.28999999165534973,0.28999999165534973,0.26600000262260437,0.273499995470047,14210922,0.0,0.0,0.3112000018358231,0.2546350009739399,1.94010222752889,-12.11439786098238,22.214149918719244,-86.8751760932583,45.505428476322585,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-06-18,0.27399998903274536,0.2784999907016754,0.26499998569488525,0.27799999713897705,7404254,0.0,0.0,0.3034500002861023,0.25248500108718874,1.8694188922643662,-8.386885194638387,20.185357141794814,-86.4939312354246,46.52014177690019,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-06-19,0.27799999713897705,0.29100000858306885,0.2680000066757202,0.2874999940395355,7973904,0.0,0.0,0.299099999666214,0.25087250098586084,1.784314725548029,-3.8783034569119663,19.223907957560975,-85.94012046227951,48.692188069621324,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-06-20,0.28949999809265137,0.28999999165534973,0.27000001072883606,0.27950000762939453,7962719,0.0,0.0,0.2947499990463257,0.25198500119149686,1.7049772240221501,-5.173873271000195,16.971247357031952,-85.22062361648163,46.962451149760234,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-06-24,0.27950000762939453,0.27950000762939453,0.2685000002384186,0.2750000059604645,6237242,0.0,0.0,0.2900499999523163,0.25347250141203403,1.6280188888311387,-5.188758487959317,14.43055887187677,-84.43061667460022,45.97313969430167,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-06-25,0.27549999952316284,0.28049999475479126,0.2694999873638153,0.2709999978542328,6092142,0.0,0.0,0.28630000054836274,0.2550475012511015,1.5469438888132572,-5.344045639128606,12.253599484000548,-83.51281497050536,45.06438101498819,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-06-26,0.27149999141693115,0.2809999883174896,0.26499998569488525,0.26899999380111694,7685606,0.0,0.0,0.282600000500679,0.25636000111699103,1.4638522240022818,-4.812458130030823,10.235605893804488,-82.48730323228368,44.58977376967588,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-06-27,0.26899999380111694,0.27149999141693115,0.2619999945163727,0.2694999873638153,3900676,0.0,0.0,0.278999999165535,0.2577600009739399,1.3848480572303137,-3.405022161338131,8.240222730966883,-81.3871276615387,44.746441455247535,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-06-28,0.2694999873638153,0.2720000147819519,0.2630000114440918,0.2630000114440918,4488689,0.0,0.0,0.275450000166893,0.25913500115275384,1.3070397208134332,-4.519872468781223,6.295945720015602,-80.17390007156924,43.04263457166865,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-07-01,0.2630000114440918,0.26649999618530273,0.2475000023841858,0.2540000081062317,12326320,0.0,0.0,0.2719999998807907,0.26007250137627125,1.2320730542143186,-6.6176440376646575,4.586220550577484,-78.89147072191129,40.730076247050654,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-07-02,0.2540000081062317,0.2554999887943268,0.2409999966621399,0.24199999868869781,11671092,0.0,0.0,0.2688500002026558,0.2609850011765957,1.1564230567465226,-9.986982143841844,3.0135827693555006,-77.43170203551198,37.81293263833112,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-07-03,0.24199999868869781,0.25600001215934753,0.23849999904632568,0.2529999911785126,7343093,0.0,0.0,0.2663499996066093,0.2622600007802248,1.082031387463212,-5.012205161559714,1.5595206338049008,-75.76225571468079,41.91940698071561,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-07-04,0.25200000405311584,0.2639999985694885,0.24699999392032623,0.2605000138282776,10539977,0.0,0.0,0.2636500015854836,0.26368500106036663,1.0102855551987886,-1.1947611372134435,-0.013273214154128066,-73.89995336432553,44.605320119157774,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-07-05,0.2605000138282776,0.2750000059604645,0.25099998712539673,0.27000001072883606,7041116,0.0,0.0,0.2627000018954277,0.2654350012540817,0.9407855581492186,2.778838515697561,-1.0303838400106073,-71.78581251010436,47.89238082051119,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-07-08,0.27000001072883606,0.2854999899864197,0.19920000433921814,0.22050000727176666,61102719,0.0,0.0,0.2572500020265579,0.26618750132620334,0.872789723922809,-14.285712134220802,-3.357595399903036,-69.50153123597667,35.92905541416333,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-07-09,0.2199999988079071,0.22349999845027924,0.2070000022649765,0.21150000393390656,18884449,0.0,0.0,0.2513000026345253,0.2657375015318394,0.8088855563352505,-15.837643566801434,-5.432992639010069,-67.14770100039938,34.25367002748203,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-07-10,0.21150000393390656,0.23549999296665192,0.2045000046491623,0.23399999737739563,15794934,0.0,0.0,0.24780000299215316,0.2662625014781952,0.7450022221853335,-5.569009462519869,-6.9339461559719355,-64.26017352040094,41.58702418774111,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-07-11,0.23399999737739563,0.23399999737739563,0.2199999988079071,0.22100000083446503,8102793,0.0,0.0,0.24295000433921815,0.26641250140964984,0.6828438902894656,-9.034782100314558,-8.806830365049018,-60.98485976103346,38.888084237480264,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-07-12,0.2214999943971634,0.23399999737739563,0.2160000056028366,0.23399999737739563,6531752,0.0,0.0,0.24005000293254852,0.2667250014841557,0.6167938915391763,-2.520310552486383,-10.000936696289319,-56.75621870726416,42.880231033525696,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-07-15,0.2329999953508377,0.2329999953508377,0.22349999845027924,0.22949999570846558,4483655,0.0,0.0,0.2376000016927719,0.26726250126957896,0.5543730599184831,-3.4090934034503992,-11.098638767466843,-51.79013545339339,41.86083574924835,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-07-16,0.22949999570846558,0.25600001215934753,0.22349999845027924,0.23899999260902405,16707406,0.0,0.0,0.23730000108480453,0.2681875009089708,0.5395313933491707,0.7163891767585717,-11.517128769789396,-50.29251231440265,44.84202332466264,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-07-17,0.2409999966621399,0.24500000476837158,0.2304999977350235,0.23899999260902405,4742344,0.0,0.0,0.23590000122785568,0.2684375006705523,0.5260397262871266,1.3141124904760348,-12.121070774917246,-48.97010867121623,44.84202332466264,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-07-18,0.23899999260902405,0.23899999260902405,0.23000000417232513,0.2304999977350235,2511417,0.0,0.0,0.23289999961853028,0.2689000006765127,0.5136772263795137,-1.030485997182384,-13.387876893793878,-47.65195206885721,42.576566841827784,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-07-19,0.23000000417232513,0.23899999260902405,0.2240000069141388,0.226500004529953,4073576,0.0,0.0,0.22854999899864198,0.26893750093877317,0.502064726377527,-0.896956673669098,-15.017430369194173,-46.43369932016576,41.51368000051255,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-07-22,0.23250000178813934,0.2329999953508377,0.21850000321865082,0.22849999368190765,5231661,0.0,0.0,0.22934999763965608,0.2684000007808208,0.4907188927133878,-0.3706143302795714,-14.54918145587247,-45.30473459117782,42.289435359737666,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-07-23,0.2290000021457672,0.23849999904632568,0.21799999475479126,0.23499999940395355,6951470,0.0,0.0,0.23169999718666076,0.2681500006467104,0.4787605597327153,1.4242564770660153,-13.593139426493156,-43.99079138924592,44.849724178282024,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-07-24,0.23600000143051147,0.23800000548362732,0.22699999809265137,0.23199999332427979,3993799,0.0,0.0,0.2314999967813492,0.26705000065267087,0.46724389332036176,0.2159812310506581,-13.31211525348713,-42.84569483510182,43.88208385404361,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-07-25,0.23250000178813934,0.2370000034570694,0.22599999606609344,0.2370000034570694,3374284,0.0,0.0,0.23309999704360962,0.26567500084638596,0.45588555981715523,1.6731044456985316,-12.261222809447283,-41.72331298386774,45.974214052894126,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-07-26,0.23749999701976776,0.25450000166893005,0.23749999701976776,0.25450000166893005,7782601,0.0,0.0,0.23514999747276305,0.2652875006198883,0.44458972637852034,8.228792006858633,-11.360317797372279,-40.32981760940995,52.63057802193454,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-07-29,0.23999999463558197,0.25949999690055847,0.23999999463558197,0.25600001215934753,4766585,0.0,0.0,0.23779999911785127,0.2652625009417534,0.43402305940786995,7.6534958406272,-10.352952915094615,-38.88285537094587,53.16325466171544,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-07-30,0.2554999887943268,0.2554999887943268,0.23600000143051147,0.24400000274181366,5840769,0.0,0.0,0.23830000013113023,0.2639125008136034,0.4242063923428456,2.3919440233096383,-9.704921367314395,-37.786769464730725,48.46766993070355,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-07-31,0.24400000274181366,0.24650000035762787,0.2395000010728836,0.24250000715255737,1964568,0.0,0.0,0.23865000158548355,0.2610875006765127,0.4158438919732968,1.613243470142934,-8.593861840528785,-37.215020897005665,47.898174606879905,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-08-01,0.2029999941587448,0.23100000619888306,0.17440000176429749,0.18359999358654022,89578312,0.0,0.0,0.23396000117063523,0.25740250051021574,0.4065572254359722,-21.525050150502302,-9.107331627747776,-36.68726457039601,31.998756784226487,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-08-02,0.18799999356269836,0.1881999969482422,0.17560000717639923,0.1770000010728836,13830013,0.0,0.0,0.22901000082492828,0.2537525001913309,0.3975155590722958,-22.710798465000163,-9.750642593766214,-36.165391668309226,30.766358493737386,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-08-05,0.17579999566078186,0.17659999430179596,0.16099999845027924,0.16979999840259552,17608985,0.0,0.0,0.22314000129699707,0.24994750022888185,0.38866389244794847,-23.90427650101451,-10.725251865826472,-35.69057865020073,29.434527995779234,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-08-06,0.17020000517368317,0.18379999697208405,0.17020000517368317,0.17960000038146973,4891741,0.0,0.0,0.2176000013947487,0.24672500044107437,0.3789105589191119,-17.463235647845,-11.804640386770062,-34.88568881667293,33.644944555983514,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-08-07,0.17960000038146973,0.18979999423027039,0.1738000065088272,0.18240000307559967,3661788,0.0,0.0,0.21264000236988068,0.2436350006610155,0.36909722549219925,-14.221218471244873,-12.721898826950607,-33.99164668980568,34.84119711619651,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-08-08,0.18240000307559967,0.1850000023841858,0.17800000309944153,0.18299999833106995,4317408,0.0,0.0,0.20724000185728073,0.24057250060141086,0.3682604254533847,-11.696585267792104,-13.855489991915832,-34.67326816199991,35.11115310768594,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-08-09,0.18479999899864197,0.1889999955892563,0.18080000579357147,0.18799999356269836,3482280,0.0,0.0,0.20059000104665756,0.23781000040471553,0.3675786588340998,-6.276488069328409,-15.651149781218344,-35.30364326399947,37.437324159869114,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-08-12,0.17020000517368317,0.19679999351501465,0.16500000655651093,0.16599999368190765,29209747,0.0,0.0,0.19158999919891356,0.23474749997258187,0.3668316421409448,-13.356649942065985,-18.384647665559392,-36.00674723627394,32.001347024763206,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-08-13,0.16599999368190765,0.1687999963760376,0.15520000457763672,0.1664000004529953,11411786,0.0,0.0,0.18382999897003174,0.23207000009715556,0.36620605054001015,-9.481585494583998,-20.786832036423604,-36.62857297006879,32.19413034676006,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-08-14,0.16619999706745148,0.17000000178813934,0.15719999372959137,0.16779999434947968,4345807,0.0,0.0,0.17635999768972396,0.22931500002741814,0.3655779587725798,-4.85371028145747,-23.092690112449073,-37.27329711087114,32.911038798222435,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-08-15,0.16779999434947968,0.16979999840259552,0.1599999964237213,0.1607999950647354,5892259,0.0,0.0,0.1740799978375435,0.22614750005304812,0.36478289204339187,-7.6286781581887215,-23.02369126490056,-38.00490511321806,31.138288046256207,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-08-16,0.16099999845027924,0.1656000018119812,0.1565999984741211,0.164000004529953,6613183,0.0,0.0,0.17277999818325043,0.2232599999755621,0.3638775004694859,-5.081603047585039,-22.610410193423437,-38.644186659657386,32.91720305847778,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-08-19,0.1687999963760376,0.1687999963760376,0.1565999984741211,0.1607999950647354,4173052,0.0,0.0,0.17187999784946442,0.22040499970316887,0.3590841670831045,-6.446359624947793,-22.0162890674239,-38.620240069744,32.02622338425111,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-08-20,0.1607999950647354,0.16099999845027924,0.15360000729560852,0.15600000321865082,4758155,0.0,0.0,0.16951999813318253,0.21752999983727933,0.3545508338759343,-7.975457210605791,-22.070519808766655,-38.646315548252744,30.684574435687395,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-08-21,0.155799999833107,0.16859999299049377,0.15000000596046448,0.1679999977350235,11386056,0.0,0.0,0.1680799975991249,0.215004999935627,0.35044250041246416,-0.047596302501265224,-21.825074928746567,-38.6475670951525,37.71005947993057,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-08-22,0.16779999434947968,0.1842000037431717,0.16359999775886536,0.17260000109672546,10750383,0.0,0.0,0.16703999787569046,0.21258250027894973,0.34721416706840197,3.3285460319346414,-21.423448469887514,-38.77481956631381,40.211697273042326,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-08-23,0.17319999635219574,0.18320000171661377,0.16519999504089355,0.17180000245571136,6196933,0.0,0.0,0.16541999876499175,0.21030250005424023,0.3422375004738569,3.856851492172682,-21.34187719008219,-38.55071412014799,39.9114906664987,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-08-26,0.17180000245571136,0.1746000051498413,0.16619999706745148,0.1703999936580658,3710696,0.0,0.0,0.16585999876260757,0.20821249969303607,0.33799083369473615,2.7372452244837167,-20.34099825556488,-38.39699810288709,39.357727513717435,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-08-27,0.1703999936580658,0.18700000643730164,0.16500000655651093,0.17299999296665192,12819582,0.0,0.0,0.16651999801397324,0.20648749954998494,0.3345158338546753,3.891421468870614,-19.35589399993517,-38.27272772992566,40.99507742923063,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-08-28,0.17599999904632568,0.17839999496936798,0.15459999442100525,0.15700000524520874,22569463,0.0,0.0,0.16543999910354615,0.20408749990165234,0.32800750037034354,-5.1015437041044445,-18.936730969182346,-37.779624041760265,34.772952803145685,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-08-29,0.15700000524520874,0.16140000522136688,0.14880000054836273,0.1550000011920929,11116134,0.0,0.0,0.1648599997162819,0.20144999958574772,0.323465833812952,-5.980831336380994,-18.163315931847986,-37.721397895074574,34.07671024565656,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-08-30,0.15479999780654907,0.1550000011920929,0.1459999978542328,0.14900000393390656,11633498,0.0,0.0,0.16335999965667725,0.1984249994158745,0.3180408337463935,-8.790398967280932,-17.671664287474837,-37.61021278981458,32.00628693551343,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-09-02,0.14920000731945038,0.15160000324249268,0.1356000006198883,0.1379999965429306,13655630,0.0,0.0,0.16107999980449678,0.19636249914765358,0.31252416695157686,-14.328286124645167,-17.96804354003783,-37.168859271584466,28.578121485939832,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-09-03,0.13860000669956207,0.1444000005722046,0.1289999932050705,0.1316000074148178,21370958,0.0,0.0,0.15864000022411345,0.19436499923467637,0.30430416675905386,-17.044876935889928,-18.38036639890526,-36.128051973546135,26.78081860760598,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-09-04,0.1316000074148178,0.14000000059604645,0.12720000743865967,0.13899999856948853,4773251,0.0,0.0,0.15574000030755997,0.19198999926447868,0.29364583355685075,-10.748684798390132,-18.881191257770666,-34.61851750492866,32.098287602214924,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-09-05,0.13819999992847443,0.1395999938249588,0.1316000074148178,0.13899999856948853,5868880,0.0,0.0,0.15238000005483626,0.18993999920785426,0.2817375005533298,-8.780680850854928,-19.774665320449703,-32.58263495813873,32.098287602214924,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-09-06,0.14000000059604645,0.14139999449253082,0.1316000074148178,0.13179999589920044,4945785,0.0,0.0,0.14837999939918517,0.1873849991708994,0.27083583337565265,-11.174015074214767,-20.815433436131556,-30.81233128003631,29.667060967233397,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-09-09,0.13179999589920044,0.14059999585151672,0.12839999794960022,0.1324000060558319,4500919,0.0,0.0,0.1445800006389618,0.18495749942958356,0.26237250007689,-8.424397931457458,-21.83069024783943,-29.505760178608455,30.14192667945821,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-09-10,0.13439999520778656,0.1348000019788742,0.12620000541210175,0.13199999928474426,7750752,0.0,0.0,0.14048000127077104,0.18228249959647655,0.25503916703164575,-6.036447828386493,-22.93280946785609,-28.527644707270166,29.99652266967587,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-09-11,0.13379999995231628,0.13459999859333038,0.12780000269412994,0.1281999945640564,4944249,0.0,0.0,0.13760000020265578,0.17951249964535237,0.2468575002004703,-6.831399436595318,-23.347956006127465,-27.280921381942118,28.585751844215807,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-09-12,0.1281999945640564,0.16920000314712524,0.1281999945640564,0.1451999992132187,41878143,0.0,0.0,0.13662000000476837,0.17737999968230725,0.24392166684071223,6.28019265711525,-22.97891518240006,-27.279932947432084,41.77808550990518,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-09-13,0.15039999783039093,0.15860000252723694,0.13699999451637268,0.14259999990463257,6604007,0.0,0.0,0.13597999960184098,0.17528249956667424,0.2398516669869423,4.86836323148655,-22.422375343799402,-26.920458061182977,40.54447705378023,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-09-16,0.1428000032901764,0.16599999368190765,0.1428000032901764,0.16359999775886536,18111225,0.0,0.0,0.13853999972343445,0.1736599996685982,0.2370816670358181,18.088637278372925,-20.223425090512805,-26.750979171088,52.69436741353088,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-09-17,0.16500000655651093,0.1876000016927719,0.16019999980926514,0.1809999942779541,13895759,0.0,0.0,0.14347999840974807,0.17230999954044818,0.2363775002459685,26.149983470906506,-16.731473047176543,-27.10389129204484,59.99000492835416,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-09-18,0.18700000643730164,0.1876000016927719,0.16060000658035278,0.17080000042915344,17867959,0.0,0.0,0.14665999859571457,0.17077999971807004,0.23563416699568432,16.459840491328247,-14.123434337846149,-27.523244232574346,54.66751154042745,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-09-19,0.17080000042915344,0.17260000109672546,0.1581999957561493,0.1671999990940094,9463957,0.0,0.0,0.14947999864816666,0.16903499960899354,0.2346108337243398,11.85442909158072,-11.568610646351877,-27.950897694859123,52.884111069412704,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-09-20,0.16660000383853912,0.16699999570846558,0.15600000321865082,0.15600000321865082,7460912,0.0,0.0,0.1518999993801117,0.16657249964773654,0.23339833381275335,2.699146711830686,-8.808476968679638,-28.631667190318783,47.673415252645235,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-09-23,0.15600000321865082,0.16220000386238098,0.15299999713897705,0.15700000524520874,1810333,0.0,0.0,0.15435999929904937,0.16409749947488309,0.2322483339657386,1.7102914991886973,-5.933972307313646,-29.343949783040923,48.16451014846986,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-09-24,0.15800000727176666,0.16279999911785126,0.15279999375343323,0.15639999508857727,1663829,0.0,0.0,0.1567999988794327,0.16190749928355216,0.2311683338135481,-0.25510446027680866,-3.154579267001461,-29.961211982372625,47.874183556576135,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-09-25,0.1565999984741211,0.1889999955892563,0.1565999984741211,0.17839999496936798,20121422,0.0,0.0,0.16181999891996385,0.16030499897897243,0.22984250038862228,10.245949919703435,0.94507342293807,-30.25441391042755,57.89572677006479,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-09-26,0.17839999496936798,0.18359999358654022,0.17440000176429749,0.18000000715255737,4803572,0.0,0.0,0.1652999997138977,0.16021499931812286,0.22859250033895176,8.89292647556113,3.1738603859917385,-29.912399102962826,58.52032730020887,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-09-27,0.18019999563694,0.2395000010728836,0.17900000512599945,0.19380000233650208,47904526,0.0,0.0,0.17041999995708465,0.16063499934971331,0.22695750047763188,13.719048459866801,6.091449962326532,-29.222431947982734,63.5436358553557,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-09-30,0.19380000233650208,0.19679999351501465,0.1842000037431717,0.19499999284744263,9082755,0.0,0.0,0.1735599994659424,0.1612649992108345,0.2252908336619536,12.353072970426807,7.624097178727326,-28.41919194421782,63.952438769558924,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-10-01,0.19499999284744263,0.1995999962091446,0.18199999630451202,0.1834000051021576,4680327,0.0,0.0,0.17380000054836273,0.1613599993288517,0.22364000032345455,5.523592936424363,7.709470297008555,-27.84832807392513,57.267281908372205,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-10-02,0.1899999976158142,0.1899999976158142,0.17800000309944153,0.18700000643730164,4583918,0.0,0.0,0.17542000114917755,0.16147499941289425,0.22194833382964135,6.601302709077298,8.636012873191406,-27.246581838800378,58.709832171709785,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-10-03,0.18700000643730164,0.18700000643730164,0.18000000715255737,0.18240000307559967,3974737,0.0,0.0,0.17694000154733658,0.1614599995315075,0.22038500048220158,3.0857926305614862,9.587515211659774,-26.737301005860832,56.103667466141125,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-10-04,0.18240000307559967,0.18459999561309814,0.1793999969959259,0.18240000307559967,2335659,0.0,0.0,0.17958000153303147,0.16131999976933004,0.2189216670890649,1.57033161738196,11.31911839189886,-26.31154242777647,56.103667466141125,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-10-07,0.1881999969482422,0.1881999969482422,0.17900000512599945,0.186599999666214,4393488,0.0,0.0,0.18254000097513198,0.16183499991893768,0.21763916711012524,2.224169315981933,12.79389567557409,-25.640682204481465,58.07441203115208,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-10-08,0.18700000643730164,0.19660000503063202,0.1809999942779541,0.19380000233650208,5675938,0.0,0.0,0.18628000169992448,0.16251999996602534,0.21640833367904028,4.036933953163392,14.619740178972524,-24.90122852336077,61.28339744891916,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-10-09,0.1940000057220459,0.2199999988079071,0.1940000057220459,0.2094999998807907,10698617,0.0,0.0,0.18939000219106675,0.16356250010430812,0.21512083373963833,10.618299517962898,15.790601189323809,-23.967150340134648,67.18203647699092,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-10-10,0.20999999344348907,0.21899999678134918,0.20000000298023224,0.20600000023841858,4721684,0.0,0.0,0.19199000149965287,0.1646925002336502,0.21390416709085305,7.297254351441339,16.574829592893146,-23.00640867660181,64.81143096986395,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-10-11,0.20600000023841858,0.2084999978542328,0.19059999287128448,0.1940000057220459,3747328,0.0,0.0,0.19201000183820724,0.16544250026345253,0.21356250047683717,1.0364063667451497,16.058450236455755,-22.53204570369024,57.340642947229725,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-10-14,0.1907999962568283,0.1907999962568283,0.1679999977350235,0.1746000051498413,10631191,0.0,0.0,0.1899700030684471,0.16578750051558017,0.21322166721026103,-8.090749944909941,14.586444983887281,-22.24641018677775,47.75651121233278,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-10-15,0.1746000051498413,0.18979999423027039,0.1746000051498413,0.1793999969959259,3787037,0.0,0.0,0.18957000225782394,0.16637250036001205,0.21298333381613097,-5.36477561891167,13.943110698952657,-21.88473277273336,49.98403479554635,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-10-16,0.18199999630451202,0.18199999630451202,0.17319999635219574,0.17880000174045563,3700956,0.0,0.0,0.18875000178813933,0.16664250046014786,0.21266916717092196,-5.27152315413061,13.266424391704579,-21.642378781585446,49.6987833221514,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-10-17,0.17900000512599945,0.18000000715255737,0.17000000178813934,0.17299999296665192,3608288,0.0,0.0,0.18781000077724458,0.166652500256896,0.21233166716992855,-7.885633219371709,12.695579416890912,-21.51312026221487,46.911740448124114,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-10-18,0.17299999296665192,0.18299999833106995,0.17100000381469727,0.18000000715255737,4424282,0.0,0.0,0.18757000118494033,0.16685750037431718,0.21209833386043708,-4.035823417689851,12.41328724459978,-21.33012205361728,50.51833366985631,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-10-21,0.22849999368190765,0.2590000033378601,0.20550000667572021,0.2150000035762787,54256033,0.0,0.0,0.1904100015759468,0.16797250062227248,0.21208583389719327,12.914238641253265,13.35784183158086,-20.799754733408708,63.771123348414626,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-10-22,0.22450000047683716,0.2280000001192093,0.1995999962091446,0.2029999941587448,11522256,0.0,0.0,0.19133000075817108,0.1687225006520748,0.21206500045955182,6.099405923968954,13.39922062482676,-20.438308873954867,58.03220155728805,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-10-23,0.20800000429153442,0.21199999749660492,0.19499999284744263,0.19699999690055847,4450627,0.0,0.0,0.19008000046014786,0.16972250044345855,0.21202333370844523,3.640570509079651,11.99457936543377,-19.951027335111547,55.35007891854112,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-10-24,0.19699999690055847,0.2150000035762787,0.19699999690055847,0.20550000667572021,10575233,0.0,0.0,0.19003000110387802,0.17098500058054925,0.21204000040888787,8.140822755342546,11.138404221811768,-19.36191272833905,58.291057240472774,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-10-25,0.20749999582767487,0.2150000035762787,0.20550000667572021,0.210999995470047,7630899,0.0,0.0,0.19173000007867813,0.17253500036895275,0.21213166701296965,10.05058957046954,11.12527873688142,-18.666079987763435,60.12142284100099,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-10-28,0.21150000393390656,0.23800000548362732,0.210999995470047,0.23399999737739563,23862941,0.0,0.0,0.19766999930143356,0.17493500038981438,0.21249500028789042,18.37911580126089,12.996255101013466,-17.675709944793695,66.70217178640443,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-10-29,0.23399999737739563,0.24500000476837158,0.22349999845027924,0.2290000021457672,13892650,0.0,0.0,0.2026299998164177,0.1773700002580881,0.21249083367486796,13.013868801875677,14.24141597878682,-16.528163972719035,64.22109736185308,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-10-30,0.2290000021457672,0.23999999463558197,0.22300000488758087,0.2370000034570694,7155673,0.0,0.0,0.20844999998807906,0.17982000038027762,0.2126908337076505,13.696331720135795,15.921476780811714,-15.45474845077468,66.37612447274623,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-10-31,0.2370000034570694,0.23999999463558197,0.23100000619888306,0.2345000058412552,3421213,0.0,0.0,0.2146000012755394,0.1822075005620718,0.21285333372652532,9.273068242047595,17.777808604773988,-14.397628934403905,65.05739232622312,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-11-01,0.2345000058412552,0.23600000143051147,0.22450000047683716,0.22599999606609344,2939094,0.0,0.0,0.219200000166893,0.18456250056624413,0.21289083374043305,3.102187907857256,18.767354958011424,-13.30650675581844,60.645662009165925,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-11-04,0.22699999809265137,0.2280000001192093,0.2134999930858612,0.2224999964237213,6129597,0.0,0.0,0.21994999945163726,0.18681500032544135,0.2130116670082013,1.159353024979091,17.736797938320283,-12.298230914155198,58.87523424606932,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-11-05,0.2224999964237213,0.23000000417232513,0.2175000011920929,0.2224999964237213,5387026,0.0,0.0,0.22189999967813492,0.1890775002539158,0.21318250025312105,0.27039060227881145,17.35928356369276,-11.307213289357392,58.87523424606932,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-11-06,0.2199999988079071,0.22050000727176666,0.1995999962091446,0.20749999582767487,8004311,0.0,0.0,0.22294999957084655,0.19106000028550624,0.21300333353380363,-6.929806581256419,16.691091404630065,-10.30187316050384,51.414872650945334,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-11-07,0.20749999582767487,0.20999999344348907,0.19779999554157257,0.20999999344348907,3798819,0.0,0.0,0.22339999824762344,0.19268000014126302,0.21298666683336098,-5.998211687218272,15.943532325014587,-9.53424314958914,52.495303021095545,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-11-08,0.21199999749660492,0.21649999916553497,0.20000000298023224,0.20399999618530273,3114893,0.0,0.0,0.22269999831914902,0.19421500004827977,0.2128116668512424,-8.396947586433077,14.666734425141307,-8.738556056685507,49.642056208614505,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-11-11,0.20399999618530273,0.2134999930858612,0.2029999941587448,0.2070000022649765,4035771,0.0,0.0,0.2199999988079071,0.19530000016093255,0.21245333353678386,-5.909089369714744,12.647208718187958,-8.073929973370557,51.0739628417455,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-11-12,0.2045000046491623,0.20649999380111694,0.1972000002861023,0.19840000569820404,3278131,0.0,0.0,0.2169399991631508,0.1957350004464388,0.21206500021119912,-8.546138810945445,10.83352423856078,-7.700469077168321,46.95237025838121,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-11-13,0.19859999418258667,0.20749999582767487,0.19419999420642853,0.2004999965429306,5205356,0.0,0.0,0.2132899984717369,0.1964775003492832,0.21143583357334136,-5.99653149254493,8.556958477467228,-7.074644335946731,48.05471005172352,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-11-14,0.20100000500679016,0.20749999582767487,0.1899999976158142,0.19380000233650208,3427396,0.0,0.0,0.2092199981212616,0.19714250043034554,0.21061750029524168,-7.370230342809901,6.126278029624207,-6.397853856401777,44.85230695905316,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-11-15,0.19380000233650208,0.21150000393390656,0.19380000233650208,0.20250000059604645,6344553,0.0,0.0,0.2068699985742569,0.19830500036478044,0.21005500021080176,-2.112436800081387,4.319103499014755,-5.593772980519172,49.55342487074653,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-11-18,0.20999999344348907,0.20999999344348907,0.19359999895095825,0.19539999961853027,3017809,0.0,0.0,0.2041599988937378,0.19926500022411348,0.20954166688024997,-4.290752019335072,2.456527069038167,-4.904354732469253,46.09964020812006,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-11-19,0.19599999487400055,0.28600001335144043,0.19220000505447388,0.21449999511241913,89508591,0.0,0.0,0.20335999876260757,0.20071750022470952,0.2088458334406217,5.47796834067443,1.316526229621081,-3.892025558758961,55.15481677418639,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-11-20,0.2150000035762787,0.22200000286102295,0.20000000298023224,0.2029999941587448,15539625,0.0,0.0,0.20290999859571457,0.20133250020444393,0.2075749999533097,0.044352453626276656,0.7835289333161611,-3.0073466218330234,49.73688945430539,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-11-21,0.1899999976158142,0.20000000298023224,0.1899999976158142,0.1979999989271164,8501175,0.0,0.0,0.2017099991440773,0.2017824999988079,0.20646666660904883,-1.8392743209080753,-0.035930199462799454,-2.2687277744017385,47.549856455081155,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-11-22,0.19580000638961792,0.20100000500679016,0.1889999955892563,0.19259999692440033,6489318,0.0,0.0,0.20056999921798707,0.20175249986350535,0.20537999980151653,-3.9736761852028737,-0.5861144948976075,-1.7662381641429865,45.23633698017389,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-11-25,0.1956000030040741,0.19580000638961792,0.18060000240802765,0.1850000023841858,8094508,0.0,0.0,0.198369999229908,0.20150250010192394,0.20423833318054677,-6.7399288690960635,-1.5545717152052512,-1.3395296739933469,42.12952777380537,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-11-26,0.18479999899864197,0.18479999899864197,0.17520000040531158,0.17759999632835388,4826469,0.0,0.0,0.19628999829292298,0.20135749988257884,0.2031474998841683,-9.521627249024716,-2.5166689061052883,-0.8811331680725071,39.29933612562288,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-11-27,0.17980000376701355,0.1817999929189682,0.17499999701976776,0.17739999294281006,5324892,0.0,0.0,0.19397999793291093,0.20111749954521657,0.20207583320637543,-8.547275578297077,-3.548921216923215,-0.47424456747390037,39.222643065812974,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-11-28,0.17880000174045563,0.1817999929189682,0.17159999907016754,0.18060000240802765,3690877,0.0,0.0,0.19265999794006347,0.20107249952852727,0.20103499988714854,-6.2597299185000965,-4.183815095644278,0.018653289924527975,41.199831321268896,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-11-29,0.18060000240802765,0.1850000023841858,0.17640000581741333,0.1850000023841858,4818166,0.0,0.0,0.1909099981188774,0.2011374995112419,0.20008916656176248,-3.0956973405926753,-5.084830733809968,0.5239328882685064,43.90216163937785,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-12-02,0.1850000023841858,0.23000000417232513,0.17020000517368317,0.1720000058412552,12368184,0.0,0.0,0.1885699987411499,0.20077249966561794,0.1991183331857125,-8.787184075150975,-6.077775066202306,0.8307454433955286,38.301369999984104,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-12-03,0.1754000037908554,0.18440000712871552,0.1754000037908554,0.18080000579357147,6685905,0.0,0.0,0.18519999980926513,0.20044749975204468,0.19834583327174188,-2.3758067063850707,-7.606729922618561,1.0595969905873601,43.55116794955219,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-12-04,0.18080000579357147,0.18199999630451202,0.17599999904632568,0.1770000010728836,3384682,0.0,0.0,0.182600000500679,0.199634999781847,0.19750416663785775,-3.066812383592836,-8.533072507217248,1.0788800966899823,41.893491473198544,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-12-05,0.1770000010728836,0.1777999997138977,0.17000000178813934,0.17720000445842743,5322396,0.0,0.0,0.1805200010538101,0.19891499988734723,0.19658500005801519,-1.8391295014412512,-9.247668020991316,1.1852378506215777,42.01858265342257,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-12-06,0.17679999768733978,0.17820000648498535,0.17139999568462372,0.17339999973773956,2530858,0.0,0.0,0.17860000133514403,0.19839999973773956,0.19570083332558472,-2.9115350271731706,-9.979837917726156,1.3792309242057625,40.24580604868791,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-12-09,0.17599999904632568,0.17800000309944153,0.16979999840259552,0.17419999837875366,4093988,0.0,0.0,0.17752000093460082,0.19838999956846237,0.1948608332624038,-1.8702132370257627,-10.519682786056725,1.811121428032752,40.81196235680977,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-12-10,0.17319999635219574,0.17599999904632568,0.16899999976158142,0.17499999701976776,2268577,0.0,0.0,0.17726000100374223,0.19827999956905842,0.19406083325544993,-1.2749655710126933,-10.601169362013838,2.174146242098549,41.409792321269165,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-12-11,0.1770000010728836,0.1770000010728836,0.1720000058412552,0.17299999296665192,2159857,0.0,0.0,0.1768200010061264,0.19813499934971332,0.19326083324849605,-2.160393630662935,-10.75781583947488,2.522066173102977,40.313514301470384,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-12-12,0.17000000178813934,0.1738000065088272,0.17000000178813934,0.1720000058412552,3135890,0.0,0.0,0.17596000134944917,0.1981099996715784,0.19244833340247472,-2.250508909879806,-11.180656382236602,2.941914938417902,39.74692366744712,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-12-13,0.1720000058412552,0.17299999296665192,0.16279999911785126,0.16660000383853912,5682453,0.0,0.0,0.1741200014948845,0.19777499958872796,0.1916450000057618,-4.318859172859758,-11.96056030490907,3.1986222352693128,36.74371191297236,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-12-16,0.17020000517368317,0.1746000051498413,0.1671999990940094,0.17319999635219574,2952180,0.0,0.0,0.17424000054597855,0.19672999940812588,0.19097166657447814,-0.596880274634968,-11.431911213241428,3.0152812388019945,42.465658345266306,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-12-17,0.17319999635219574,0.1770000010728836,0.164000004529953,0.17000000178813934,7316975,0.0,0.0,0.17316000014543534,0.19590499959886074,0.19037166660030683,-1.824900874706598,-11.610218983690332,2.9065948191604423,40.5504069725835,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-12-18,0.16920000314712524,0.16920000314712524,0.164000004529953,0.164000004529953,3337444,0.0,0.0,0.17186000049114228,0.19507999978959562,0.18963000004490216,-4.573487686911989,-11.902808757175194,2.8740176888693565,37.1657310252775,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-12-19,0.1656000018119812,0.17100000381469727,0.14300000667572021,0.16300000250339508,12871569,0.0,0.0,0.17044000029563905,0.19401749968528748,0.18881749995052816,-4.365171191820475,-12.152254012082977,2.753981879922023,36.617149817343645,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-12-20,0.1581999957561493,0.1632000058889389,0.15039999783039093,0.15600000321865082,5975526,0.0,0.0,0.16870000064373017,0.19264249987900256,0.18786749988794327,-7.5281549357548,-12.428461658414166,2.5416849608939396,32.95070800915043,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-12-23,0.1599999964237213,0.1648000031709671,0.15479999780654907,0.16300000250339508,6956756,0.0,0.0,0.1675800010561943,0.19086750000715255,0.18738833318154016,-2.73302215296169,-12.200871782826082,1.8566613868334074,39.47698493467413,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-12-27,0.16419999301433563,0.16859999299049377,0.16019999980926514,0.16459999978542328,4525751,0.0,0.0,0.16654000133275987,0.18925749994814395,0.18699749981363614,-1.1648862326236658,-12.00348658394442,1.208572380251152,40.89315373404995,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2024-12-30,0.17479999363422394,0.17479999363422394,0.15700000524520874,0.1607999950647354,4542998,0.0,0.0,0.1653200015425682,0.18735249973833562,0.18638749979436398,-2.7340953518373508,-11.759916855413687,0.5177385527657713,38.58400781155016,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-01-02,0.17599999904632568,0.18320000171661377,0.17000000178813934,0.1770000010728836,15223482,0.0,0.0,0.16582000106573105,0.18591499961912633,0.18602083312968412,6.7422505941974995,-10.80870214590688,-0.05689336445666193,51.228065711635324,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-01-03,0.1770000010728836,0.18000000715255737,0.1703999936580658,0.1770000010728836,6541813,0.0,0.0,0.1668600007891655,0.18468999974429606,0.18554583316047987,6.076950878437562,-9.654014283294313,-0.46125175737231117,51.22806571163532,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-01-07,0.17739999294281006,0.17919999361038208,0.16859999299049377,0.17139999568462372,3937959,0.0,0.0,0.1666800007224083,0.18341249972581863,0.18506166649361452,2.8317704234212138,-9.122878227178393,-0.8911444487898814,47.322239390698556,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-01-08,0.17100000381469727,0.17139999568462372,0.1599999964237213,0.1599999964237213,5797312,0.0,0.0,0.1656800001859665,0.18184999972581864,0.18440333319207033,-3.428297776357851,-8.89194367018543,-1.3846460484487015,40.54512688480281,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-01-09,0.16060000658035278,0.16300000250339508,0.15620000660419464,0.16300000250339508,5510132,0.0,0.0,0.1655799999833107,0.18073749989271165,0.1837699999411901,-1.5581576761539155,-8.386472048356689,-1.6501605536534225,42.864073118083795,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-01-10,0.1648000031709671,0.1648000031709671,0.15520000457763672,0.15680000185966492,3673938,0.0,0.0,0.16495999991893767,0.17940750010311604,0.18315583330889543,-4.946652560185879,-8.052896437369977,-2.046526795276981,39.44035267858672,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-01-13,0.15600000321865082,0.1597999930381775,0.15279999375343323,0.15700000524520874,2715069,0.0,0.0,0.16506000012159347,0.17823250032961369,0.18257666664818922,-4.883069714314332,-7.390627513870757,-2.3793655554827287,39.607929933018745,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-01-14,0.15479999780654907,0.17000000178813934,0.15199999511241913,0.1550000011920929,6011407,0.0,0.0,0.16425999999046326,0.1769325003027916,0.18196416671077412,-5.637403384212824,-7.162336083331995,-2.7651963015224807,38.461785403874636,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-01-15,0.15559999644756317,0.17499999701976776,0.15219999849796295,0.17440000176429749,12860876,0.0,0.0,0.16524000018835067,0.17633250020444394,0.18145916673044363,5.543452896093978,-6.290672453026171,-2.8252452705325815,52.74587376714246,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-01-16,0.17440000176429749,0.18299999833106995,0.16619999706745148,0.17319999635219574,9945017,0.0,0.0,0.1664800003170967,0.17565000019967555,0.18096916675567626,4.036518514115434,-5.220609093170837,-2.9392667554147667,51.942720421193016,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-01-17,0.17020000517368317,0.1738000065088272,0.16359999775886536,0.1720000058412552,7153939,0.0,0.0,0.16598000079393388,0.1751050002872944,0.18042750010887781,3.626946028753919,-5.211158720989776,-2.949938240219253,51.104708517044465,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-01-20,0.17000000178813934,0.1746000051498413,0.1550000011920929,0.16599999368190765,6288070,0.0,0.0,0.16488000005483627,0.17419250011444093,0.1796900000423193,0.6792780365713791,-5.34609702110397,-3.059435653950494,47.01994762407492,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-01-21,0.16599999368190765,0.16760000586509705,0.15700000524520874,0.16339999437332153,3675277,0.0,0.0,0.16407999992370606,0.1733924999833107,0.17891833322743575,-0.4144353673212555,-5.3707628994915995,-3.088466757121409,45.32915954870474,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-01-22,0.1632000058889389,0.1632000058889389,0.15700000524520874,0.16200000047683716,2438004,0.0,0.0,0.16428000032901763,0.17208000011742114,0.17823499987522762,-1.387874268087484,-4.532775327220522,-3.4533058950908915,44.403269163294496,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-01-23,0.16200000047683716,0.16200000047683716,0.15760000050067902,0.1599999964237213,2178273,0.0,0.0,0.16397999972105026,0.17100500017404557,0.17754749978582066,-2.4271272741184378,-4.108067276305022,-3.6849291708795895,43.05042199402766,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-01-24,0.1589999943971634,0.17399999499320984,0.1565999984741211,0.16580000519752502,5587530,0.0,0.0,0.16488000005483627,0.1702000003308058,0.1773991665492455,0.5579846812122593,-3.125734586151237,-4.05817364223143,47.99845404784095,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-01-27,0.16599999368190765,0.18199999630451202,0.16599999368190765,0.18199999630451202,12731356,0.0,0.0,0.1673799991607666,0.16993500031530856,0.17744083317617576,8.734614181532576,-1.5035167268668885,-4.2300482513035105,58.772912642601334,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-01-28,0.1826000064611435,0.1876000016927719,0.17520000040531158,0.18299999833106995,5501962,0.0,0.0,0.1701799988746643,0.16988500021398067,0.1775508331755797,7.533199871418157,0.1736460901857541,-4.317542657779761,59.3330462501499,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-01-29,0.18299999833106995,0.18400000035762787,0.1785999983549118,0.18359999358654022,4408973,0.0,0.0,0.17109999805688858,0.17003500014543532,0.17758416645228864,7.305666669555164,0.626340406705877,-4.25103569629421,59.68695088013606,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-01-30,0.18299999833106995,0.18299999833106995,0.17579999566078186,0.17960000038146973,2282756,0.0,0.0,0.17173999845981597,0.1700900003314018,0.17756083309650422,4.576686847643623,0.9700735641127125,-4.207477873818048,56.17701348237785,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-01-31,0.17720000445842743,0.18199999630451202,0.17000000178813934,0.17440000176429749,3408374,0.0,0.0,0.17197999805212022,0.16993500031530856,0.17748916645844778,1.4071425395899002,1.2033999664679065,-4.2561280183304815,51.90386181954869,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-02-03,0.1809999942779541,0.1809999942779541,0.17139999568462372,0.17599999904632568,5639013,0.0,0.0,0.172979998588562,0.16971000023186206,0.17738916650414466,1.745866853049781,1.9268153628144422,-4.328993942312243,53.086330811705864,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-02-04,0.1762000024318695,0.18199999630451202,0.1762000024318695,0.18019999563694,3544230,0.0,0.0,0.17465999871492385,0.1699149999767542,0.17750749985376993,3.171875050256017,2.7925720147243154,-4.277283992659699,56.1350115711073,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-02-05,0.18019999563694,0.1826000064611435,0.1785999983549118,0.18000000715255737,2016484,0.0,0.0,0.17645999938249587,0.16989500001072882,0.17762083324293296,2.0061247775413134,3.8641510176005602,-4.349621095199722,55.94857020529151,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-02-06,0.17980000376701355,0.18479999899864197,0.1770000010728836,0.18400000035762787,4536261,0.0,0.0,0.17885999977588654,0.17006999999284744,0.17775583329300085,2.8737563391377625,5.168459918509305,-4.323814953225524,58.88959801138673,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-02-07,0.18299999833106995,0.18479999899864197,0.17980000376701355,0.18199999630451202,2495886,0.0,0.0,0.18047999888658522,0.17018999978899957,0.177932499969999,0.8421971560859635,6.0461831543234785,-4.351369301451324,56.846000606624074,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-02-10,0.18000000715255737,0.1834000051021576,0.17339999973773956,0.17720000445842743,3256684,0.0,0.0,0.17999999970197678,0.17028499990701676,0.17804249996940294,-1.5555529156584753,5.705141263331968,-4.357105783012105,52.16706109518992,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-02-11,0.17980000376701355,0.17980000376701355,0.17020000517368317,0.17479999363422394,1357809,0.0,0.0,0.17917999923229216,0.17029999978840352,0.17815916662414868,-2.444472383544275,5.2143273370064485,-4.41131769117733,49.953112889529386,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-02-12,0.17100000381469727,0.1738000065088272,0.16899999976158142,0.1720000058412552,1893251,0.0,0.0,0.17802000045776367,0.1702250000089407,0.17829249997933705,-3.3816394792880384,4.579233631025737,-4.524867827492083,47.4243943097321,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-02-13,0.16979999840259552,0.17299999296665192,0.16619999706745148,0.17020000517368317,2795511,0.0,0.0,0.177080000936985,0.17015500031411648,0.17831083337465922,-3.8852471916069877,4.069819053265874,-4.573941418021442,45.81863195525522,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-02-14,0.1736000031232834,0.17479999363422394,0.16200000047683716,0.16200000047683716,5531704,0.0,0.0,0.17584000080823897,0.16990500018000604,0.17822250003616016,-7.870791781043566,3.493128879047168,-4.666919078380429,39.291734386532475,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-02-17,0.164000004529953,0.1736000031232834,0.15620000660419464,0.1581999957561493,4617311,0.0,0.0,0.17406000047922135,0.1696949999779463,0.17810916664699714,-9.111803216940336,2.572262295201589,-4.724162617484631,36.68381651779725,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-02-18,0.1581999957561493,0.16380000114440918,0.15199999511241913,0.1589999943971634,4633801,0.0,0.0,0.17194000035524368,0.16933999992907048,0.17801416665315628,-7.525884570981189,1.535372875435356,-4.872739561782515,37.62248146644826,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-02-19,0.1599999964237213,0.164000004529953,0.15760000050067902,0.1589999943971634,3702223,0.0,0.0,0.1698399990797043,0.16906499974429606,0.17789749999841054,-6.382480417615752,0.4584031801853621,-4.964937817672192,37.62248146644826,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-02-20,0.1599999964237213,0.16140000522136688,0.14659999310970306,0.15479999780654907,10115651,0.0,0.0,0.1669199988245964,0.16883499957621098,0.1778791666030884,-7.260963996760703,-1.1342439401909423,-5.084444232335627,34.507612118873226,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-02-21,0.14880000054836273,0.16419999301433563,0.1477999985218048,0.1599999964237213,4969826,0.0,0.0,0.16471999883651733,0.16875999942421913,0.17792083323001862,-2.8654701591399157,-2.3939325678392973,-5.148825822975003,41.01859408115145,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-02-24,0.1581999957561493,0.1581999957561493,0.1469999998807907,0.15279999375343323,8022418,0.0,0.0,0.16227999776601792,0.1686799991875887,0.177952499811848,-5.841757544422303,-3.7941673300895253,-5.210660504383621,35.72296798111506,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-02-25,0.15060000121593475,0.16179999709129333,0.14920000731945038,0.15800000727176666,6008545,0.0,0.0,0.1605999991297722,0.168554999306798,0.17811916656792165,-1.6189239552265569,-4.71952787502101,-5.36953290620557,41.58830351609766,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-02-26,0.1599999964237213,0.1599999964237213,0.15039999783039093,0.15479999780654907,2816408,0.0,0.0,0.15887999832630156,0.16830999925732612,0.17831249982118608,-2.5679761850029386,-5.602757395659659,-5.609534145890268,39.21671297376408,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-02-27,0.15479999780654907,0.16099999845027924,0.1501999944448471,0.15440000593662262,3706815,0.0,0.0,0.1572999984025955,0.1681499995291233,0.17844083321591217,-1.8436061636508183,-6.452572796260153,-5.767084529546574,38.917966198557544,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-02-28,0.1542000025510788,0.1599999964237213,0.15119999647140503,0.15700000524520874,3574372,0.0,0.0,0.1567999988794327,0.16764999963343144,0.17859083327154318,0.1275550811258874,-6.4718167478212925,-6.126201125606744,42.01032218964532,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-03-03,0.15639999508857727,0.16300000250339508,0.15440000593662262,0.1607999950647354,3716328,0.0,0.0,0.15705999881029128,0.16724499948322774,0.17883249993125597,2.381253204364004,-6.089868578676318,-6.479527184646256,46.29012738249897,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-03-04,0.16099999845027924,0.16099999845027924,0.15000000596046448,0.1589999943971634,4996854,0.0,0.0,0.15705999881029128,0.16693499945104123,0.17905416650076708,1.235193939620092,-5.915476486790353,-6.768436214900326,44.61060299070892,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-03-05,0.15680000185966492,0.15680000185966492,0.15060000121593475,0.15240000188350677,1596265,0.0,0.0,0.15639999955892564,0.16674499958753586,0.17922416652242343,-2.5575432779408778,-6.2040841129868,-6.962881835093512,39.0202025315739,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-03-06,0.15219999849796295,0.15600000321865082,0.14900000393390656,0.15240000188350677,4768654,0.0,0.0,0.1561599999666214,0.16647999957203866,0.17942583325008551,-2.407785658246861,-6.198942594874067,-7.215144800248929,39.0202025315739,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-03-07,0.15240000188350677,0.15240000188350677,0.1420000046491623,0.15139999985694885,6057681,0.0,0.0,0.15530000030994415,0.16634499952197074,0.1794774999221166,-2.5112687992348772,-6.639814388029004,-7.317073396857343,38.179463044256444,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-03-10,0.14159999787807465,0.15080000460147858,0.14020000398159027,0.1459999978542328,3360113,0.0,0.0,0.1546200007200241,0.16606999933719635,0.17950583323836328,-5.57495978893433,-6.894682159854551,-7.4849009966855355,33.92826530656468,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-03-11,0.14339999854564667,0.1485999971628189,0.1395999938249588,0.14259999990463257,3681115,0.0,0.0,0.1530799999833107,0.16575999930500984,0.17933083325624466,-6.846093598001503,-7.6496135224802115,-7.567485024643554,31.54648406536039,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-03-12,0.1420000046491623,0.1444000005722046,0.13699999451637268,0.14180000126361847,3659650,0.0,0.0,0.15178000032901764,0.16494499929249287,0.17900416664779187,-6.5753057344612325,-7.981447767404007,-7.85410061597157,30.99513202881262,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-03-13,0.1420000046491623,0.14959999918937683,0.1412000060081482,0.149399995803833,2319868,0.0,0.0,0.15127999931573868,0.1643499992787838,0.1788258332759142,-1.2427310420473319,-7.952540322725965,-8.094934457705182,41.46216087830406,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-03-14,0.14980000257492065,0.15479999780654907,0.14959999918937683,0.15199999511241913,2093450,0.0,0.0,0.15077999830245972,0.1638499990105629,0.1786991665760676,0.8091237721810638,-7.976808536483788,-8.309589714389512,44.56035596307638,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-03-17,0.15119999647140503,0.15760000050067902,0.1446000039577484,0.14480000734329224,3899694,0.0,0.0,0.1491799995303154,0.1633199993520975,0.17860583327710627,-2.936045180864275,-8.657849545601595,-8.558418078816524,38.485784723054735,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-03-18,0.14959999918937683,0.14959999918937683,0.14300000667572021,0.14300000667572021,785656,0.0,0.0,0.14758000075817107,0.16280999965965748,0.17848916662236056,-3.103397519258567,-9.354461601451765,-8.784380172426017,37.123277295643554,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-03-19,0.1459999978542328,0.15219999849796295,0.14480000734329224,0.1509999930858612,1919886,0.0,0.0,0.14743999987840653,0.1625349994748831,0.17844416660567125,2.414536903411961,-9.287230224410358,-8.915487366950185,46.23390488624998,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-03-20,0.25999999046325684,0.2800000011920929,0.19900000095367432,0.21199999749660492,216003953,0.0,0.0,0.15339999943971633,0.16383499950170516,0.17872416662673155,38.20078114140895,-6.369212984848348,-8.330807974123983,75.44732834768513,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-03-21,0.21649999916553497,0.2784999907016754,0.21199999749660492,0.2784999907016754,132208805,0.0,0.0,0.166109998524189,0.16665249913930893,0.1795449998229742,67.65998023961221,-0.32552804063648566,-7.180651478112379,85.00963387920066,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-03-24,0.2865000069141388,0.3059999942779541,0.24400000274181366,0.24950000643730164,75586312,0.0,0.0,0.17645999938249587,0.16833999939262867,0.1800091665238142,41.39182098515356,4.823571355093379,-6.4825405042035875,71.86516271597642,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-03-25,0.25,0.2540000081062317,0.2240000069141388,0.22949999570846558,43363351,0.0,0.0,0.18514999896287918,0.16950249932706357,0.18029666654765605,23.953549551182096,9.231427086879096,-5.986892285520634,64.46232716418768,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-03-26,0.2280000001192093,0.23649999499320984,0.21549999713897705,0.2199999988079071,19586094,0.0,0.0,0.19296999871730805,0.17041249945759773,0.18060166649520398,14.007358796844233,13.23699806734136,-5.641790153623434,61.235604662571134,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-03-27,0.23000000417232513,0.24250000715255737,0.22450000047683716,0.23149999976158142,21294445,0.0,0.0,0.20117999911308287,0.17170999944210052,0.1809724997729063,15.071081013105946,17.162657833983303,-5.118181128308912,63.61022459520097,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-03-28,0.23199999332427979,0.23649999499320984,0.20999999344348907,0.2134999930858612,12580758,0.0,0.0,0.20732999891042708,0.17268749922513962,0.18123166635632515,2.9759292952583047,20.060803382254463,-4.71450012184216,57.65674724479187,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-03-31,0.21199999749660492,0.21199999749660492,0.20000000298023224,0.20649999380111694,8320024,0.0,0.0,0.21349999755620958,0.1734499990940094,0.18143249961237112,-3.2786903209447082,23.090226965347625,-4.399708175446107,55.48201393416993,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-04-01,0.20550000667572021,0.21799999475479126,0.19200000166893005,0.20550000667572021,11689590,0.0,0.0,0.21974999755620955,0.1740824993699789,0.18158999967078368,-6.484637560391486,26.233250528631913,-4.134313736668101,55.16192080961833,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-04-02,0.20550000667572021,0.20800000429153442,0.19460000097751617,0.19499999284744263,5565686,0.0,0.0,0.2241499975323677,0.17445749901235102,0.1815999995917082,-13.004686596401033,28.484014044302334,-3.9330950415284547,51.78363194440133,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-04-03,0.19380000233650208,0.1979999989271164,0.1876000016927719,0.18880000710487366,4887918,0.0,0.0,0.22182999849319457,0.1745774991810322,0.18142749965190888,-14.88977668154933,27.066775233824842,-3.77561311489122,49.842553063977306,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-04-04,0.19200000166893005,0.19740000367164612,0.1793999969959259,0.18000000715255737,6564711,0.0,0.0,0.21198000013828278,0.1745274994522333,0.18121083304286004,-15.08632558017908,21.459369327811803,-3.6881534499904776,47.14151399723808,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-04-07,0.16899999976158142,0.1860000044107437,0.1565999984741211,0.1826999932527542,14880779,0.0,0.0,0.20529999881982802,0.1746649991720915,0.1811166662722826,-11.008283339985624,17.53928937849357,-3.5621609170367323,48.07133906721465,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-04-08,0.1835000067949295,0.20600000023841858,0.1835000067949295,0.19660000503063202,8975177,0.0,0.0,0.20200999975204467,0.1752099994570017,0.18129999960462254,-2.67808263355928,15.295930813366605,-3.3590734478223188,52.68575530142583,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-04-09,0.18520000576972961,0.1907999962568283,0.17399999499320984,0.18299999833106995,7183140,0.0,0.0,0.19830999970436097,0.17548499926924704,0.18132999961574872,-7.720236698156955,13.00681000094685,-3.2234050399203955,48.175087986187954,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-04-10,0.20399999618530273,0.20479999482631683,0.17800000309944153,0.18240000307559967,7517325,0.0,0.0,0.1934000000357628,0.17578999921679497,0.18135999962687493,-5.687692325816468,10.017635188251008,-3.0712397560319404,47.97992362431644,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-04-11,0.1808999925851822,0.20600000023841858,0.17409999668598175,0.19699999690055847,8585414,0.0,0.0,0.1917500004172325,0.176664999127388,0.18155999965965747,2.7379381861290226,8.538760571904309,-2.6960787295909694,52.97244505950943,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-04-14,0.20600000023841858,0.21899999678134918,0.19900000095367432,0.20679999887943268,12790334,0.0,0.0,0.1917800009250641,0.1778799992054701,0.1817833329240481,7.831889603670139,7.814257803958065,-2.147245105363364,56.02335390394881,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-04-15,0.20720000565052032,0.20819999277591705,0.19850000739097595,0.20260000228881836,6873827,0.0,0.0,0.1914900004863739,0.17896999940276145,0.18167999957998593,5.801870475860707,6.995586481193938,-1.4916337425635993,54.39465604594998,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-04-16,0.20180000364780426,0.20739999413490295,0.19110000133514404,0.20280000567436218,3954343,0.0,0.0,0.19227000176906586,0.18006499968469142,0.18167833300928274,5.476675408753485,6.778109074915394,-0.8880163626935571,54.46254720875975,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-04-17,0.20280000567436218,0.20280000567436218,0.1923000067472458,0.19460000097751617,2874303,0.0,0.0,0.1928500011563301,0.1810599997639656,0.1816583330432574,0.907440918171145,6.511654372989197,-0.32937287779103,51.10354726976036,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-04-22,0.19470000267028809,0.19480000436306,0.1809999942779541,0.18400000035762787,7424188,0.0,0.0,0.19325000047683716,0.18165999986231327,0.18147916632393996,-4.786545974843602,6.3800509871784525,0.09964424128471143,47.06276064273156,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-04-23,0.18400000035762787,0.18809999525547028,0.18129999935626984,0.18199999630451202,3859376,0.0,0.0,0.19318000078201295,0.18238999992609023,0.18123749966422717,-5.787350881169422,5.91589498343941,0.6359060702107784,46.31857762690626,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-04-24,0.18400000035762787,0.19519999623298645,0.1800999939441681,0.18940000236034393,4870285,0.0,0.0,0.19246000051498413,0.18317499980330468,0.18086583303908507,-1.5899398038305412,5.068923554879098,1.2767291231399107,49.5004016880495,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-04-25,0.1923999935388565,0.1965000033378601,0.18709999322891235,0.19370000064373016,5107123,0.0,0.0,0.19353000074625015,0.1841474998742342,0.18057166635990143,0.08784162498036105,5.095100872085606,1.9802849397234323,51.30651059729426,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-04-28,0.19930000603199005,0.20999999344348907,0.19370000064373016,0.19900000095367432,5543864,0.0,0.0,0.1951900005340576,0.1852624997496605,0.18025499967237313,1.951944469077413,5.358613209803298,2.778008979716997,53.51337827412447,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-04-29,0.20080000162124634,0.2021999955177307,0.1915999948978424,0.19529999792575836,5089511,0.0,0.0,0.1950200006365776,0.18621999956667423,0.179928332939744,0.14357362745708604,4.725593969702813,3.4967625854885456,51.750074082049636,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-04-30,0.1995999962091446,0.1995999962091446,0.1899999976158142,0.19499999284744263,3006287,0.0,0.0,0.1938400000333786,0.1870749995112419,0.17966999957958857,0.5984279889931335,3.6161970011017743,4.121444842756364,51.60160388594954,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-05-02,0.19990000128746033,0.19990000128746033,0.1898999959230423,0.19140000641345978,6259523,0.0,0.0,0.19272000044584275,0.18788499981164933,0.17941083299616972,-0.684928408742877,2.573382994406371,4.7233306227726635,49.75685126131836,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-05-05,0.19140000641345978,0.1972000002861023,0.19030000269412994,0.19300000369548798,3722870,0.0,0.0,0.19174000024795532,0.18889999985694886,0.17916499972343444,0.6571416740916041,1.5034411821901261,5.433538999548858,50.60210374213395,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-05-06,0.19529999792575836,0.19789999723434448,0.1860000044107437,0.18610000610351562,3790448,0.0,0.0,0.19089000076055526,0.18974249996244907,0.1789866664757331,-2.5092957399314035,0.604767407583058,6.009293149316368,46.93501872747829,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-05-07,0.1859000027179718,0.19339999556541443,0.18000000715255737,0.1875,4392722,0.0,0.0,0.19124000072479247,0.19064499996602535,0.1787991665303707,-1.9556581837575853,0.31209880084615454,6.625217368472759,47.76219714471449,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-05-08,0.21780000627040863,0.22599999606609344,0.19499999284744263,0.20579999685287476,44039390,0.0,0.0,0.19362000077962876,0.1921399999409914,0.17881416653593382,6.290670397790576,0.7702721136108515,7.4523365028685635,57.16219837512804,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-05-09,0.20880000293254852,0.20880000293254852,0.1979999989271164,0.20319999754428864,11168383,0.0,0.0,0.19500000029802322,0.19365499988198281,0.17878249982992808,4.205126786529824,0.6945343093956156,8.318767254179027,55.6305356243604,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-05-12,0.23999999463558197,0.2948000133037567,0.20919999480247498,0.29179999232292175,129198424,0.0,0.0,0.2048099994659424,0.1974049996584654,0.17956083305180073,42.47350865866529,3.751171358521084,9.937671987474502,77.62880608928887,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-05-13,0.2985999882221222,0.2985999882221222,0.2662000060081482,0.2669999897480011,44745720,0.0,0.0,0.21160999834537506,0.20034499950706958,0.180114999661843,26.175507696107235,5.622800102833598,11.231713007360524,67.53538394281048,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-05-14,0.27239999175071716,0.2858000099658966,0.23999999463558197,0.25,41062774,0.0,0.0,0.21707999855279922,0.20279499962925912,0.18058333297570547,15.164916927707562,7.044058753744078,12.299953870350738,61.62079652097031,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-05-15,0.2515999972820282,0.2565999925136566,0.2409999966621399,0.2443999946117401,10978190,0.0,0.0,0.22201999872922898,0.2052849993109703,0.1809324995925029,10.080171160529245,8.152080996872122,13.45943916837175,59.76402946430774,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-05-16,0.24660000205039978,0.2612000107765198,0.24400000274181366,0.2549999952316284,12280050,0.0,0.0,0.22837999761104583,0.20808499902486802,0.18142916622261207,11.65601099003387,9.753225211468692,14.692143141720369,62.092432518389806,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-05-19,0.2596000134944916,0.28459998965263367,0.25920000672340393,0.2680000066757202,30212394,0.0,0.0,0.23587999790906905,0.21100999936461448,0.18187499965230625,13.617097274620683,11.786170617194536,16.01924385869754,64.78400551948116,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-05-20,0.27059999108314514,0.2793999910354614,0.2547999918460846,0.2639999985694885,17952585,0.0,0.0,0.24366999715566634,0.21230999939143658,0.18238333302239576,8.34325179592568,14.770852929263706,16.408662937071103,63.294815204967115,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-05-21,0.2639999985694885,0.2651999890804291,0.25,0.25220000743865967,14643993,0.0,0.0,0.25013999789953234,0.21165249980986117,0.18283499975999196,0.8235426386925618,18.184287038540322,15.761478977054741,58.987118843224216,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-05-22,0.2513999938964844,0.26179999113082886,0.2492000013589859,0.25040000677108765,12995548,0.0,0.0,0.2545999988913536,0.21167499981820584,0.18331666650871437,-1.649643416557212,20.278728763440796,15.469588144700088,58.334918220386626,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-05-23,0.25099998712539673,0.26460000872612,0.22499999403953552,0.23759999871253967,28840214,0.0,0.0,0.2580399990081787,0.21187749989330767,0.18375499981145063,-7.921252664007014,21.78735313476724,15.304345520237975,53.781097334854294,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-05-26,0.23600000143051147,0.23600000143051147,0.21799999475479126,0.22179999947547913,20775058,0.0,0.0,0.25103999972343444,0.21192249990999698,0.18412333317101,-11.64754631937875,18.458398626880378,15.098122687778886,48.724838837243965,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-05-27,0.22040000557899475,0.22339999675750732,0.20999999344348907,0.21060000360012054,17337352,0.0,0.0,0.2454000011086464,0.21140000000596046,0.18439999992648762,-14.180928016018546,16.083255015008188,14.642082478436325,45.462013989154194,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-05-28,0.210999995470047,0.21960000693798065,0.210999995470047,0.21539999544620514,3896501,0.0,0.0,0.2419400006532669,0.21144750006496907,0.18468999986847243,-10.969664022237158,14.42083759747869,14.487790468109848,47.097061824311446,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-05-30,0.21940000355243683,0.23340000212192535,0.21279999613761902,0.22460000216960907,10766175,0.0,0.0,0.2399600014090538,0.21190000027418138,0.18501999986668427,-6.401066489935929,13.24209584642051,14.528159348646325,50.1800174001217,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-06-02,0.23000000417232513,0.23999999463558197,0.22699999809265137,0.23680000007152557,12588686,0.0,0.0,0.23814000189304352,0.2126825001090765,0.1855599998186032,-0.5626949739085763,11.969720955372855,14.616566241101147,54.00764287434152,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-06-03,0.2370000034570694,0.2460000067949295,0.22920000553131104,0.23680000007152557,10186636,0.0,0.0,0.23502000123262407,0.21372750028967857,0.18602666643758614,0.7573818524235544,9.962452615637389,14.890786564401695,54.007642874341535,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-06-04,0.23759999871253967,0.26600000262260437,0.23579999804496765,0.257999986410141,24325532,0.0,0.0,0.2344200000166893,0.21545749977231027,0.1867016663153966,10.058862892147824,8.801039770914496,15.402022930173636,60.174111548357,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-06-05,0.26420000195503235,0.26600000262260437,0.24619999527931213,0.2476000040769577,10847817,0.0,0.0,0.23395999968051912,0.21714749969542027,0.1872883329788844,5.830058307003124,7.742433142762742,15.94288669326899,56.19376661779925,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-06-09,0.2476000040769577,0.2476000040769577,0.23199999332427979,0.23280000686645508,10870738,0.0,0.0,0.23219999969005584,0.2184000000357628,0.18778333303829034,0.25840102377267055,6.31868115935591,16.304251555290854,51.021531830011014,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-06-10,0.2540000081062317,0.27140000462532043,0.24539999663829803,0.27000001072883606,95716362,0.0,0.0,0.23544000089168549,0.2202350001782179,0.18858166647454103,14.678903205173684,6.903989239295953,16.784947495386646,60.790477166395526,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-06-11,0.27399998903274536,0.2800000011920929,0.2590000033378601,0.2630000114440918,24957748,0.0,0.0,0.23956000208854675,0.22223500050604345,0.18931499992807707,9.784608929365888,7.795802435733864,17.38900805032515,58.428859523304794,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-06-12,0.25999999046325684,0.2653999924659729,0.23999999463558197,0.25,17778572,0.0,0.0,0.2435000017285347,0.22392500042915345,0.18995666665335495,2.6694037886339754,8.74176677988865,17.882148794380605,54.21640548437971,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-06-13,0.24899999797344208,0.25459998846054077,0.23980000615119934,0.24199999868869781,12739118,0.0,0.0,0.24616000205278396,0.22505000047385693,0.19053999992708365,-1.689959103589103,9.380138429006264,18.111682880224443,51.74411370088999,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-06-16,0.24220000207424164,0.24940000474452972,0.24220000207424164,0.24719999730587006,4420922,0.0,0.0,0.24842000156641006,0.22606000043451785,0.1912116665393114,-0.49110548782194563,9.891179814612611,18.225004010433608,53.2368084392504,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-06-17,0.24799999594688416,0.25,0.2401999980211258,0.24199999868869781,5477237,0.0,0.0,0.24894000142812728,0.22704500034451486,0.1917849998921156,-2.7878214427636476,9.643463212310008,18.385171140722164,51.52053778620597,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-06-18,0.24379999935626984,0.24379999935626984,0.23600000143051147,0.2378000020980835,5701781,0.0,0.0,0.24904000163078308,0.2279200002551079,0.19234999989469845,-4.5133309745811685,9.266409859615585,18.492331884524123,50.115222340794496,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-06-19,0.23639999330043793,0.2443999946117401,0.23399999737739563,0.2362000048160553,4058737,0.0,0.0,0.24686000347137452,0.22896000035107136,0.19295166656374932,-4.318236452003994,7.81796081973119,18.661841293516503,49.560615637065794,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-06-23,0.23479999601840973,0.24040000140666962,0.22619999945163727,0.2345999926328659,6132016,0.0,0.0,0.24556000232696534,0.2302250001579523,0.19354833314816158,-4.463271538622193,6.660876168310145,18.949616570303743,48.97690777469169,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-06-24,0.23800000548362732,0.2590000033378601,0.23499999940395355,0.2524000108242035,15134580,0.0,0.0,0.24752000272274016,0.2319850005209446,0.1943516665448745,1.97156110527749,6.696554590559835,19.363525224714646,55.28622072150221,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-06-25,0.25619998574256897,0.25619998574256897,0.24320000410079956,0.24799999594688416,6336750,0.0,0.0,0.24532000124454498,0.2334500003606081,0.19505999982357025,1.0924485116350744,5.084600927651063,19.68112404991346,53.52430664093639,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-06-26,0.24779999256134033,0.2558000087738037,0.23819999396800995,0.25040000677108765,7795081,0.0,0.0,0.24406000077724457,0.23486750051379204,0.19577499988178412,2.5977243192872255,3.913909009694052,19.968075931867375,54.378355077357085,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
2025-06-27,0.2529999911785126,0.257999986410141,0.24660000205039978,0.25200000405311584,9452180,0.0,0.0,0.24426000118255614,0.23619250059127808,0.1965349999566873,3.1687557656134393,3.415646377883333,20.178340063261285,54.972409265710475,,5.629,-0.5781,0.80651003,-0.52687,69.176,1.7872341,12.6,Xbrane Biopharma AB (publ),Healthcare,"Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden."
